

AD_____

Award Number: W81XWH-07-1-0277

TITLE: The Integrative Studies of Genetic and Environmental Factors in Systemic Sclerosis

PRINCIPAL INVESTIGATOR: Xiaodong Zhou

CONTRACTING ORGANIZATION: University of Texas Health Science Center
Houston, Texas 77030-3900

REPORT DATE: May 2009

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 01-05-2009		2. REPORT TYPE Annual		3. DATES COVERED 9 APR 2008 - 8 APR 2009	
4. TITLE AND SUBTITLE The Integrative Studies of Genetic and Environmental Factors in Systemic Sclerosis				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-07-1-0277	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Xiaodong Zhou Email: xiaodong.zhou@uth.tmc.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Texas Health Science Center Houston, Texas 77030-3900				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT During this second year of the project, we established multiple primary cell strains from normal controls and SSc patients. We performed stimulation assays with silica in 82 primary fibroblast strains. Our results showed that silica activate fibroblasts toward fibrotic changes. However, different fibroblast strains obtained from different individuals showed different responses in terms of the gene expression of the ECM components. Using longitudinal linear models in analysis of association between specific genotypes and dynamic changes of gene expression of the fibroblasts in responding to silica stimulation, we identified that specific SNPs were associated with either single gene expression, or paired gene expression such as CTGF/SPARC and COL1A2/COL3A1, which suggest a strong biological correlation between these genes. Moreover, some SNPs and/or their corresponding genes were found to be associated with both SSc susceptibility and the fibrotic changes of human fibroblast in response to silica stimulation. These SSc susceptibility genes include not only previously identified ones, but also some novel ones, such as HLA-DPB1 and APBA1. These observations supported our original proposal that genetic elements within SSc fibroblasts might contribute to susceptibility to fibrotic process. Integrative studies of genetic and environmental factors with human fibroblasts may facilitate the discovery of potential pathogenesis of SSc. In this year, we will continuously obtain more human fibroblasts, especially SSc fibroblasts. We also will continuously perform stimulation assays of newly obtained human fibroblasts for a better chance to identify genetic components inside SSc patients contributing to susceptibility to environmental stimuli. Meanwhile, we will try to explore which specific bio-pathways associated with which specific genetic factors involved in silica induced fibrotic changes. Therefore, our studies are fulfilled with original proposal in the grant.					
15. SUBJECT TERMS Scleroderma (SSc), fibroblasts, fibrosis, silica, environmental particles, susceptibility.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC
			UU	56	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Page

Introduction.....

Body.....

Key Research Accomplishments.....

Reportable Outcomes.....

Conclusion.....

References.....

Appendices.....

Introduction:

This project aims to study interactions between genetic and environmental factors in a viable system - human fibroblasts. Fibroblasts with a scleroderma (SSc) susceptible genetic background may be more vulnerable to environmental triggers. Studies of fibroblasts with and without SSc susceptible backgrounds in response to potential environmental triggers will provide a great opportunity to understand etiopathogenesis of SSc.

Body:

According to our SOW, there are four major tasks that will be performed for this project. 1. We will culture and genotype human fibroblasts obtained from skin biopsies. 2. We will stimulate cultured fibroblasts with silica, cellulose, titanium oxide and carbon particles individually, and then examine potential alterations of fibroblasts in terms of proliferation, ROS production, collagen synthesis, cytokine expression and release. 3. We will apply comprehensive statistical analysis to identify the association of genetic susceptibility genes and these environmental factors in terms of the degree of their profibrotic effects. 4. We will also study specific biological pathways triggered by risk elements in cultured fibroblasts.

During this second year of the project, we have been continuously obtaining skin biopsies from SSc patients and normal controls. Currently, we have a total of 166 skin fibroblast strains including 65 from SSc patients and 101 from normal controls. These primary fibroblast cultures were established from each skin biopsy, and maintained in healthy condition for proposed functional studies.

We have performed stimulation assays on 82 primary fibroblast strains for part of our proposed studies. Each of these 82 fibroblast strain was stimulated with silica particles for evaluation of their responses toward potentially fibrotic changes over 5 different time-points. Meanwhile, we have genotyped 79 of these fibroblast strains with both the HLA subtyping and the genome-wide single nucleotide polymorphism (SNP) profiling (Illumina Human 317 K SNP panel). It should be noted that the studies of performing genome-wide SNP profiling were funded by our other research projects. This addition of genotyping appeared to be very important in understanding complexity of human genetics, especially in association with environmental factors. We examined gene expression changes of COL1A2, COL3A1, CTGF, SPARC and TIMP3 of these fibroblasts in five different time points (0, 1, 2, 3, and 5 days) in response to silica stimulation. The COL1A2, COL3A1, CTGF, SPARC and TIMP3 are three major components of the extracellular matrix (ECM), which are actively involved in fibrotic changes of the tissues. Using longitudinal linear models in the analysis of association between specific genotypes and dynamic changes of gene expression of the fibroblasts in responding to silica stimulation, we identified that specific SNPs were associated with either single gene expression, or paired gene expression (Table 1). Notably, the paired gene expressions of CTGF/SPARC and COL1A2/COL3A1 were associated with multiple SNPs, which suggest a strong biological correlation between these genes. HLA-DQB1*0301 is a positive marker for SSc susceptibility. Interestingly, HLA-DQB1*0301 positive fibroblast strains showed a significant up-regulation (>2-fold increase of transcript) of COL1A2, COL3A1, CTGF and SPARC in response to silica stimulation after 24 hours, which was significantly different from the response of HLA-DQB1*0301 negative fibroblast strains ($P < 0.05$ for all 4 genes).

While HLA-DQB1*0301 is a previously identified SSc genetic marker, we are recently exploring novel SSc susceptibility markers using a genome-wide SNP association (GWAS) approach. Collaborating with Dr. Eun Bong Lee (Seoul National University College of Medicine, Seoul, Korea), we demonstrated that specific SNPs of the HLA-DPB1 and -DPB2 were strongly associated with SSc susceptibility in both Koreans and US Caucasians (see attached manuscript 1). Incorporating this information into our data of gene expression changes of the fibroblasts, we revealed that specific SNPs of HLA-DPB1 also was associated with gene expression changes of the COL1A2 of the fibroblasts in response to silica stimulation ($p = 0.00042$). Moreover, several other potential SSc susceptibility regions identified from the Dr. Lee's GWAS also showed an overlap with the genetic regions associated with gene expression changes

of the ECM components of the fibroblasts in response to silica stimulation. The figure 1 demonstrates an example of the association between genetic regions and expression changes of the COL1A2 of the fibroblasts in response to silica stimulation. The figure 2 represents a GWAS results from Dr. Lee's data that shows log P-values of the genome-wide SNPs in association with SSc. Comparing both figures, we can find the overlapped chromosomal regions such as on chromosome 1, 3, 6 and 10. In addition to Dr. Lee's GWAS studies of SSc, Dr. Maureen Mayes, a professor in our division of Rheumatology in UT Health Science Center, just completed the GWAS studies of SSc with 1678 SSc Caucasian SSc patients and 5530 Caucasian controls (Dr. Mayes' personal communication). We had a chance to pre-examine this unpublished GWAS data. Remarkably, multiple SNPs that showed an association with SSc susceptibility in the GWAS studies were overlapped with the SNPs that also were associated with the gene expression of the ECM of the fibroblasts in response to silica stimulation (Table 2). Further studies of the genes corresponding to these SNPs may provide important knowledge to understand pathogenesis of SSc. For instance, the ABCA7 (ATP-binding cassette, subfamily A, member 7) encodes a transmembrane protein involved in energy-dependent transport of a wide spectrum of substrates. Dysregulation of ATP-dependent membrane transportation may lead to various pathological events associated with vascular and immune functions. The APBA1 (amyloid beta A4 precursor protein-binding, family A, member 1) is a candidate gene for Alzheimer disease. However, serum amyloid protein was reported to be lower in SSc patients (*Pilling D., et al. J Immunol. 2003;171:5537-46*). According to Philing's studies, low levels of SAP may augment pathological processes leading to fibrosis. The EGKD (diacylglycerol kinase delta) is a gene encoding protein regulates protein kinase C and epidermal growth factor receptor signaling (*Proc. Nat. Acad. Sci. 103: 15485-15490, 2006*). The RBMS3 (RNA-binding motif protein, single strand-interacting 3) is a gene closely related to c-myc involving in regulation of DNA replication, gene transcription, apoptosis and cell cycle.

Overall, above data strongly support our original proposal that genetic elements within SSc fibroblasts might contribute to susceptibility to fibrotic process. Integrative studies of genetic and environmental factors with human fibroblasts may facilitate the discovery of potential pathogenesis of SSc.

Our efforts in studying specific biological pathways triggered by risk elements in cultured fibroblasts have been continued through last year. Previously, we demonstrated that silica stimulation on fibroblasts induced TGF- β signaling (reported in original proposal), which may contribute to fibrosis. Recently, we identified that SPARC inhibition attenuated profibrotic effects of TGF- β on human fibroblasts. Last year, we applied SPARC siRNA in bleomycin-induced mouse fibrotic model, and demonstrated an anti-fibrotic effect of SPARC inhibition *in vivo* (attached manuscript 2). Although, the *in vivo* studies of anti-fibrosis were funded by other projects, the results represent a successful example of translational studies of medical diseases.

Table 1. Associations between SNPs and gene expression of COL1A2, COL3A1, CTGF, SPARC and TIMP3 of human fibroblasts in response to silica stimulation

Associated genes	rs number	Gene Name	P-value for testing genetic effect to gene expression				
			COL1A2	COL3A1	CTGF	SPARC	TIMP3
COL1A2/COL3A1	rs10484710	COL21A1	6×10^{-13}	1.7×10^{-5}	> 0.01	> 0.01	> 0.01
COL1A2/COL3A1	rs5972761	DMD	7.4×10^{-12}	8.8×10^{-4}	> 0.01	> 0.01	> 0.01
COL1A2/COL3A1	rs5972763	DMD	7.4×10^{-12}	8.8×10^{-4}	> 0.01	> 0.01	> 0.01
COL1A2/COL3A1	rs3734061	FAT2	5.4×10^{-12}	7.9×10^{-4}	> 0.01	> 0.01	> 0.01
COL1A2/COL3A1	rs998076	FAT2	5.4×10^{-5}	3×10^{-4}	> 0.01	> 0.01	> 0.01
COL1A2/COL3A1	rs2288777	FAT2	3.7×10^{-4}	1.3×10^{-3}	> 0.01	> 0.01	> 0.01
COL1A2/COL3A1	rs1410871	GBP4	7.1×10^{-8}	6.5×10^{-4}	> 0.01	> 0.01	> 0.01
COL1A2/COL3A1	rs2196426	hCG_2015138	7.2×10^{-14}	1×10^{-7}	> 0.01	> 0.01	> 0.01
COL1A2/COL3A1	rs4803831	OPA3	4.2×10^{-8}	1.3×10^{-5}	> 0.01	> 0.01	> 0.01
COL1A2/COL3A1	rs3809251	PARP11	7.9×10^{-3}	1.3×10^{-7}	> 0.01	> 0.01	> 0.01
COL1A2/COL3A1	rs2061783	XRCC4	2.9×10^{-14}	6.3×10^{-8}	> 0.01	> 0.01	> 0.01
COL1A2/COL3A1	rs10947541	DEF6	2.9×10^{-14}	6.3×10^{-8}	> 0.01	> 0.01	> 0.01
COL1A2/COL3A1/SPARC	rs2289722	C4orf20	2.1×10^{-5}	3.6×10^{-12}	> 0.01	7.5×10^{-5}	> 0.01
CTGF/SPARC	rs6810854	ACOX3	> 0.01	> 0.01	3.4×10^{-15}	8.8×10^{-6}	> 0.01
CTGF/SPARC	rs9375513	C6orf174	> 0.01	> 0.01	1.4×10^{-8}	1.4×10^{-3}	> 0.01
CTGF/SPARC	rs2236026	KIAA0408	> 0.01	> 0.01	1.4×10^{-8}	1.4×10^{-3}	> 0.01
CTGF/SPARC	rs3922703	PLCXD2	> 0.01	> 0.01	1.5×10^{-8}	9.4×10^{-5}	> 0.01
CTGF/COL3A1	rs3788926	ZRSR2	> 0.01	1.1×10^{-8}	2.8×10^{-5}	> 0.01	> 0.01
CTGF/TIMP3	rs11702035	C21orf51	> 0.01	> 0.01	1.4×10^{-7}	> 0.01	8.8×10^{-5}
CTGF/SPARC/TIMP3	rs10507399	HSPH1	> 0.01	> 0.01	7.8×10^{-9}	2.9×10^{-6}	3.9×10^{-8}
SPARC/CTGF/COL1A2/COL3A1	rs13082485	PIK3CA	2.5×10^{-7}	1.8×10^{-3}	2.5×10^{-3}	1.9×10^{-7}	> 0.01
COL1A2	rs437444	CELSR2	1.1×10^{-7}	> 0.01	> 0.01	> 0.01	> 0.01
COL1A2	rs10478113	MCC	1×10^{-7}	> 0.01	> 0.01	> 0.01	> 0.01
COL1A2	rs3793726	PRKCQ	1.5×10^{-7}	> 0.01	> 0.01	> 0.01	> 0.01
COL1A2	rs7918923	PRKCQ	1.6×10^{-7}	> 0.01	> 0.01	> 0.01	> 0.01
COL1A2	rs6445245	PTPRG	1.5×10^{-7}	> 0.01	> 0.01	> 0.01	> 0.01
COL1A2	rs2864780	RAB31	7.8×10^{-8}	> 0.01	> 0.01	> 0.01	> 0.01
COL1A2	rs3731895	RESP18	6×10^{-8}	> 0.01	> 0.01	> 0.01	> 0.01
COL3A1	rs11564394	CDH2	> 0.01	1.5×10^{-7}	> 0.01	> 0.01	> 0.01
COL3A1	rs11754507	DSE	> 0.01	1.6×10^{-11}	> 0.01	> 0.01	> 0.01
COL3A1	rs7052934	SPANXN3	> 0.01	3.4×10^{-8}	> 0.01	> 0.01	> 0.01
COL3A1	rs11817964	ZNF365	> 0.01	1.6×10^{-7}	> 0.01	> 0.01	> 0.01
TIMP3	rs10499156	LAMA2	> 0.01	> 0.01	> 0.01	> 0.01	5.4×10^{-8}
TIMP3	rs13154825	SLIT3	> 0.01	> 0.01	> 0.01	> 0.01	8.1×10^{-9}
TIMP3	rs1476707	C19orf29	> 0.01	> 0.01	> 0.01	> 0.01	6.1×10^{-9}

Table 2. The SNPs associated with both SSc susceptibility and gene expression changes of the fibroblasts in response to silica stimulation.

SNP ID	Gene symbol	Gene ID	P-value for SNP-SSc association	P-value for testing genetic effect on gene expression	Associated gene expression of
rs3752228	ABCA7	NM_019112.2	0.0004622	0.0046	COL1A2
rs1831555	APBA1	NM_001163.2	0.0001345	0.0077	CTGF
rs1977552	APBA1	NM_001163.2	0.0001478	0.0068	CTGF
rs2781530	APBA1	NM_001163.2	0.0002292	0.0077	CTGF
rs673576	C21orf88	NM_153754.1	0.0002405	0.0057	TIMP3
rs7584554	DGKD	NM_152879.2	0.0002883	0.0017	CTGF
rs4981200	NPAS3	NM_022123.1	0.0006308	0.0067	CTGF
rs4981200	NPAS3	NM_022123.1	0.0006308	0.0049	SPARC
rs4981200	NPAS3	NM_022123.1	0.0006308	0.0068	COL3A2
rs3773046	RBMS3	NM_001003792	0.0001188	0.0072	COL1A2

Figure 1. Identification of genetic loci associated with high sensitivity of fibroblasts over-expressing the *COL1A2* in response to silica stimulation. (X axis indicates SNP positions on different chromosomes, Y axis indicates log p values of association between over-expression of the *COL1A2* and SNP genotypes). The gene expression of the *COL1A2* was examined with real-time RT-PCR. The genome-wide SNP typing on human fibroblasts was performed with Illumina's human 317 K SNP panel.





Figure 2. Identification of the major loci associated with systemic sclerosis in genome wide scan. A total of 440,734 SNPs were evaluated in 133 patients with SSc and 557 healthy controls. Distribution of $-\log_{10} P$ values are plotted against chromosomes. The genome-wide SNP typing was performed with Affymetrix Whole Genome Human SNP Array 5.0.



Key Research Accomplishments

- Obtained a total of 166 human fibroblast strains (65 SSc patients and 101 normal controls).
- Completed silica stimulation in 82 fibroblast strains and obtained RNA and protein extracts from each of the experiments.
- Completed genotyping for 79 fibroblast strains (34 SSc and 45 controls) with both HLA subtyping and genome-wide SNP profiling.

- Identified that the paired gene expressions of CTGF/SPARC and COL1A2/COL3A1 were associated with multiple SNPs, which suggest a strong biological correlation between these genes.
- Identified some novel genes and SNPs associated with both SSc susceptibility and human fibroblast response to silica stimulation in terms of their gene expression changes of the ECM components.
- Demonstrated that specific inhibition of SPARC, a major ECM component, attenuated mouse fibrosis induced by bleomycin *in vivo*.

Reportable Outcomes

During this second year period, we reported that SPARC inhibition attenuated profibrotic effects of TGF- β *in vitro* and bleomycin *in vivo* (oral presentation) in annual meeting of American College of Rheumatology 2008. We have one full article accepted by the European Journal of Human Genetics (2009). We have two manuscripts submitted for publication (one received comments for revision) and two manuscripts in preparation.

Importantly, we established a total of 166 human fibroblast strains (65 SSc and 101 controls), which is close to our minimum target of 200 (100 SSc and 100 controls) that can be used for many studies toward human health.

Abstract:

1. Wang J, Lai S, Sonnylal S, Arnett F.C., Crombrugghe B and **Zhou XD**. Application of Sparc and Ctgf siRNAs in fibrotic murine models of scleroderma (SSc) *in vitro* and *in vivo*. Arthritis & Rheuma 2008;58 (9); supplement for ACR annual meeting.
2. **Zhou XD**, Tan FK, Guo XJ, Tejpal N, Kahan BD, Stepkowski SN, Arnett FC. Up-take Of Silica And Carbon Nanotubes By Human Macrophages Induces Activation Of T Cells And Fibroblasts *In Vitro* - Potential Implication For Pathogenesis Of Fibrosing Diseases. Arthritis & Rheuma 2007;56 (9);s245. supplement for ACR annual meeting.

Referred articles (underline for corresponding author):

1. Xiong M, Arnett FC, Xiong H and **Zhou XD**. Differential Dynamic Properties of Scleroderma Fibroblasts in Response to Perturbation of Environmental Stimuli -Application of State-Space Model in Studies of human Complex Disease. PLoS ONE, 2008 Feb, 3(2):e1693.
2. Momiao Xiong, Gang Peng , Li Luo , Yun Zhu , Pengfei Hu , Shengjun Hong , Jinying Zhao , **Zhou XD**, John Reveille, Li Jin , Christopher Amos. Gene and Pathway-Based Analysis -Second Wave of Genome-wide Association Studies. European Journal of Human Genetics (2009) (in press).

Manuscript submitted (see attachment)

1. **Zhou XD**, Lee JU, Arnett FC, Xiong MM, Park MY, Yoo YK, Shin ES, Reveille JD, Mayes MD, Kim JH, Song R, Choi JY, Park JA, Lee YJ, Lee EU, Song YW, Lee EB. HLA-DPB1 and DPB2 are culprit genetic loci for susceptibility to systemic sclerosis, Genome-wide association study in Koreans with Replication in North Americans. Arthritis Rheum (2009). (received comments for revision)
2. Wang JC, Lai SL, Guo XJ, Zheng XF, de Crembrugghe B, Arnett FC and **Zhou XD**. Attenuation of fibrosis in vitro and in vivo with Sparc siRNA. (submitted to Arthritis Rheum 2009)

Manuscript in preparation

1. **Zhou XD**, Jagannath C, Tan FK, Guo XJ, Tejpal N, Kahan BD, Stepkowski SN, Arnett FC. Up-take of silica and carbon nanotubes by human macrophages induces activation of T cells and fibroblasts in vitro – potential implication for pathogenesis of fibrotic diseases.

2. JC Wang, Xiong H, Tan FK, Arnett FC, Zhou XD. Studies of genetic and environmental factors in human fibroblasts showed novel gene-gene interactions.

Conclusion

During this second year of the project, we established multiple primary cell strains from normal controls and SSc patients. We performed stimulation assays with silica in 82 primary fibroblast strains. Our results showed that silica activate fibroblasts toward fibrotic changes. However, different fibroblast strains obtained from different individuals showed different responses in terms of the gene expression of the ECM components. Using longitudinal linear models in analysis of association between specific genotypes and dynamic changes of gene expression of the fibroblasts in responding to silica stimulation, we identified that specific SNPs were associated with either single gene expression, or paired gene expression such as CTGF/SPARC and COL1A2/COL3A1, which suggest a strong biological correlation between these genes. Moreover, some SNPs and/or their corresponding genes were found to be associated with both SSc susceptibility and the fibrotic changes of human fibroblast in response to silica stimulation. These SSc susceptibility genes include not only previously identified ones, but also some novel ones, such as HLA-DPB1 and APBA1. These observations supported our original proposal that genetic elements within SSc fibroblasts might contribute to susceptibility to fibrotic process. Integrative studies of genetic and environmental factors with human fibroblasts may facilitate the discovery of potential pathogenesis of SSc. In this year, we will continuously obtain more human fibroblasts, especially SSc fibroblasts. We also will continuously perform stimulation assays of newly obtained human fibroblasts for a better chance to identify genetic components inside SSc patients contributing to susceptibility to environmental stimuli. Meanwhile, we will try to explore which specific bio-pathways associated with which specific genetic factors involved in silica induced fibrotic changes. Therefore, our studies are fulfilled with original proposal in the grant.

Appendices (two manuscripts submitted for publication)

HLA-DPB1 and DPB2 are culprit genetic loci for susceptibility to systemic sclerosis

-Genome-wide association study in Koreans with Replication in North Americans

Xiaodong Zhou^{1*}, Jong Eun Lee^{2*}, Frank. C. Arnett¹, Momiao Xiong³, Min Young Park²,
Yeon Kyeong Yoo², Eun Soon Shin², John. D. Reville¹, Maureen D. Mayes¹, Jin Hyun
Kim⁴, Ran Song⁴, Ji Yong Choi⁵, Ji Ah Park⁴, Yun Jong Lee⁴, Eun Young Lee^{4,5}, Yeong
Wook Song^{4,5}, Eun Bong Lee^{4,5}

1. Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas Medical School at Houston, Houston TX. USA; 2. DNA Link Inc, Seoul, Korea; 3. Department of Biostatistics, University of Texas School of Public Health; 4. Department of Internal Medicine, Department of Immunology, Seoul National University College of Medicine, Seoul, Korea; 5. Clinical Research Institute, Seoul National University Hospital, Seoul Korea

Correspondence should be addressed to: Eun Bong Lee M.D., Ph.D

Department of Internal Medicine

Seoul National University College of Medicine

Seoul, Korea

Tel ; 822-2072-3944

Fax: 822-762-9662

E-mail: leb7616@snu.ac.kr

*Both authors equally contributed to the study.

Abstract

We performed a genome-wide association study using the Affymetrix Human SNP Array 5.0 in 137 patients with systemic sclerosis and 564 controls from Korea. The SNPs (rs3128930, rs7763822, rs7764491, rs3117230 and rs3128965) of HLA-DPB1 and –DPB2 on chromosome 6 formed a distinctive peak with log p-values ($p < 1 \times 10^{-14}$) for association with SSc susceptibility. Subtyping analysis of HLA-DPB1 showed that DPB1*1301 ($p = 7.61 \times 10^{-8}$) and DPB1*0901 ($p = 2.56 \times 10^{-5}$) are the most susceptible subtypes for SSc in Koreans. We then replicated the results in 1,106 SSc patients and 2,747 controls from a US Caucasian population. Remarkably, two pairs of SNPs, rs7763822/rs7764491 and rs3117230/rs3128965, showed strong association with Caucasian SSc patients who have either circulating anti-DNA topoisomerase I or anti-centromere autoantibodies, respectively. Therefore, our GWAS and confirmatory studies revealed that the region of HLA-*DPB1* and –*DPB2* contains the most susceptible loci to SSc, especially those patients with anti-topoisomerase I or anti-centromere autoantibodies.

Introduction

Systemic sclerosis (SSc) is a rare and complex connective tissue disease of unknown etiology characterized by fibrosis and vasculopathy of skin and internal organs, as well as several, mutually exclusive, disease-specific circulating autoantibodies¹. SSc can be clinically sub-classified based on patterns of skin fibrosis into limited and diffuse forms. In addition, the majority of SSc patients (90%) have circulating anti-nuclear autoantibodies (ANA)². The three most common autoantibodies (auto-Abs) are anti-DNA topoisomerase I (topo I), anti-RNA polymerase III, and anti-centromere antibodies, in which the first two auto-Abs tend to be associated with diffuse SSc^{2; 3}, the last one being strongly correlated with limited SSc, although these associations are not complete^{2; 4}.

Genetic predisposition is widely believed to contribute to SSc. Several genetic regions have been reported to be associated with SSc susceptibility, including the major histocompatibility complex (MHC) or HLA-class II⁵, protein tyrosine phosphatase non-receptor 22 (*PTPN22*)⁶, allograft inflammatory factor 1 (*AIF1*)⁷, tumor necrosis factor (TNF)⁸, cytotoxic lymphocyte antigen-4 (CTLA-4)⁹, transforming growth factor (TGF- β)¹⁰ and connective tissue growth factor (CTGF)¹¹. However, the low prevalence of SSc (approximately 0.00070--0.049%)^{12; 13} and clinical/serological heterogeneity make genetic studies of SSc difficult with some differing results reported for the same genes in different ethnic groups. To address such difficulties, we conducted a two-step genetic association study in four independent populations to identify the susceptibility markers for SSc.

Material and Methods

Study Subjects

We examined 4 different ethnic populations (Koreans, Caucasian Americans, African Americans and Hispanics). Korean study population was composed of 151 SSc patients diagnosed according to the ACR preliminary criteria for SSc¹⁴. All the patients were enrolled from Seoul National University Hospital between January 1998 and 2007. Genomic DNA was extracted from whole blood using standard methods. A total of 137 cases which passed the DNA quality check were entered into the GWAS using Affymetrix Genome-Wide Human SNP Array 5.0. A total of 133 cases which showed >95% of call rates, were finally entered into the case-control analysis. The mean age at diagnosis was 42 years ranging from 4 to 67 years. Mean duration of the disease was 10 years and the mean time from diagnosis to blood sampling was 5 years.

The 600 healthy controls were randomly selected from 10,000 healthy Koreans belonging to Korean Association Resource (KARE) Project, based on the frequency-matching on sex with the cases. The mean age of the controls was 52.5 years. The same platform (Affymetrix Genome-Wide Human SNP Array 5.0) was used for the whole-genome scan of the controls. After excluding cases with low call rate less than 95%, mismatched sex and potential relatives, a total of 557 controls were finally entered into the case-control analysis. The institutional review board of Seoul National University Hospital approved the study and all patients and controls provided written consents.

SSc patients of Caucasians, African Americans and Hispanics who met the ACR criteria for SSc and corresponding controls (sex and ethnically matched) were enrolled in the Division of Rheumatology, University of Texas Health Science Center at Houston (UTHSC-Houston)^{6; 7}. In addition, 2,300 Caucasian controls were selected from NIH data base of Genotype and Phenotype (dbGaP) found at <http://www.ncbi.nlm.nih.gov/gap>. The study was approved by the institutional review boards of the University of Texas Health Science Center at Houston. All the individual patients and controls provided written consent.

GWAS analysis

Among the 500,568 SNPs present in Affymetrix Whole Genome Human SNP Array 5.0, 440,734 SNPs were accessible after excluding hidden SNPs. Q-Q plot was obtained in the condition of p-value > 0.0001 for Hardy-Weinberg equilibrium and call-rate > 0.95 (Figure 1). Finally cluster quality analysis was performed, which led to 349,209 SNPs which can be analyzed. The most significant SNPs were determined to be rs3128930, re7763822, rs7764491, rs3117230 and rs3128965 and they went into the fine mapping process.

Fine mapping

For Koreans, we performed a fine mapping focusing on HLA-*DPB1* and -*DPB2* regions with 137 SSc cases and 548 healthy controls in whom DNA was available. For HLA-*DPB1*, highly variable exon 2 of the gene was DNA-sequenced to determine subtype of HLA-*DPB1*. For the other region including

HLA-DPB2, total 22 tag SNPs were selected with r^2 threshold of 0.8 and minor allele frequency over 5% in HapMap Japanese panel data (release 22) using the Haploview version 4.1^{15; 16}. In tag SNPs, 17 SNPs which are included in Affymetrix SNP chip were forced to be included.

For replication studies, TaqMan Assays were used for SNPs rs3128930, rs7763822, rs7764491, rs3117230 and rs3128965 genotyping with an ABI 7900HT Fast Real-Time PCR System in Caucasian, African American and Hispanic populations. Genotyping results of all five SNPs passed quality tests for Hardy-Weinberg ($p > 0.001$) and calling rate (>95%). Two groups of Caucasian controls from the NIH data base and the UTHSC-Houston showed concordant association with Caucasian SSc patients.

Statistical analysis

The association of specific SNPs with the disease or a subset of the disease was analyzed by the comparison of minor allele frequencies of the cases and controls, with significance determined by p-values of chi-square tests, Cochran-Armitage Trend test, and Jonckheere-Terpstra tests. The odds ratio of cases' having a selected SNP compared with the controls' and its relevant 95% confidence intervals were also determined. For GWAS, The threshold for declaring significance after Bonferroni correction for adjusting multiple tests was $p < 1.43 \times 10^{-7}$. It was $p < 2.2 \times 10^{-3}$ for the fine mapping study ($n=22$) and $p < 0.01$ for the replication study ($n=5$). All the association tests were based on the comparison of alleles. PLINK¹⁷ and SAS 9.1.3 (SAS Institute Inc., Cary, NC,

USA) were used for the statistical analysis. Linkage disequilibrium analysis for HLA-DPB1 and –DPB2 regions was performed with Haploview, version 4.1¹⁶.

Results

We first examined a Korean population who are relatively homogenous in which 62.2% of patients are positive for anti-topo I auto-Abs (based on Korean patients enrolled in this project). We performed a genome-wide association study (GWAS) in 137 Korean SSc patients and 564 sex-matched Korean controls using the Affymetrix Human SNP Array 5.0 containing 440,734 accessible human SNPs. The GWAS showed a distinctive peak of SNP log p-value ($p = 7.84 \times 10^{-15}$ for association with SSc) (Figure 1). The peak was formed with the SNPs rs3128930, rs7763822, rs7764491, rs3117230 and rs3128965, which were located in the region of HLA-DPB1 and –DPB2 (a pseudogene) on chromosome 6p (Figure 1, 2). Fine mapping analysis of this region confirmed that rs3128930, rs7763822 and rs7764491 were the culprit SNPs for associations with Korean SSc (Figure 2, Table 1). Interestingly, the association was even stronger in patients who were positive for anti-topo I auto-Abs (rs3128930, $p = 1.70 \times 10^{-22}$, OR 5.15, 95% CI 3.62-7.34) (Table 1). These SNPs also were associated with the diffuse form of SSc, but not the limited forms of SSc (Supplementary Table 1). Subtyping of HLA-DPB1 showed that HLA-DPB1*1301 (21.0% in SSc vs. 5.5% in controls), DPB1*0901 (12.0% vs. 2.6%) and DPB1*030101 (10.0% vs. 4.3%) were significantly more represented in anti-topo 1 positive patients than controls (Table 2). SNPs corresponding to previous SSc associated reported genes, such

as *PTPN22*, *AIF1*, *TNF*, *CTLA-4*, *TGFB* and *CTGF*, fell within the significance thresholds of 10^{-5} - 10^{-6} advocated for gene-based scans, as well as the Bonferroni correction for multiple comparisons¹⁸.

To confirm these results, we used TaqMan Assays to reexamine the 5 SNPs with the strongest association from the Korean GWAS screen in 1,106 US Caucasian SSc patients (collected from US), of whom 16% were positive for anti-topo I, and 2,747 normal controls, of which 447 were from our local collections (Houston, Texas, US.) and 2,300 were from the NIH data base of Genotype and Phenotype (dbGaP) (<http://www.ncbi.nlm.nih.gov/gap>). The SNPs rs7763822 and rs7764491 showed highly significant associations with SSc patients who were positive for anti-topo I auto-Abs ($p = 7.58 \times 10^{-17}$ and 4.84×10^{-16} , respectively) (Table 3). The HLA-DPB1*1301 allele which occurs in only 3% of US Caucasians was found in 25% of anti-topo I positive patients and conferred the strongest risk by exact logistic regression ($p=0.0001$, OR=14) of any HLA class II allele (unpublished results). The SNPs rs3128965 and rs3117230 showed strong associations with SSc patients who were positive for anti-centromere auto-Abs ($p = 3.20 \times 10^{-5}$ and 1.12×10^{-3} , respectively) (Table 3). In addition, the pair of anti-topo I associated SNPs also showed a weaker association with the diffuse form of SSc ($p = 0.0070$ and 0.014 for rs7763822 and rs7764491 respectively) (Supplementary Table 2). The genetic concordance of the patients with anti-topo I positivity and the diffuse form of SSc supports clinical observations that these two traits within SSc commonly overlap^{2, 3}. However, the anti-centromere associated SNP pairs did not show strong associations with the limited form of SSc that usually occurs in patients with anti-

centromere auto-Abs^{2; 4}. The SNP rs3128930 showed only a marginal p value of 0.041 in the limited form of SSc patients who were positive for anti-centromere auto-Abs (Supplementary table 2). Further analysis of Caucasian patients who are negative for anti-topo I or anti-centromere autoantibodies indicated that they have marginal or no association with the genotypes of all the 5 SNPs (Table3). In contrast, highly significant differences were observed in the comparisons of patients with and without anti-topo I or anti-centromere autoantibodies using corresponding anti-topo I or anti-centromere associated SNP pairs (rs7763822 and rs7764491 pair, $p \leq 2.86 \times 10^{-18}$ or rs3128965 and rs3117230 pair, 4.77×10^{-4} respectively) (Supplementary Table 3). Interestingly, marginally significant differences ($0.05 > p \geq 0.01$) were also observed in the comparison of patients with the limited and the diffuse forms of SSc using both pairs of SNPs but the autoantibody associations were the strongest, perhaps because HLA alleles are specific immune response genes (Table 3, and supplementary Table 2).

Finally, we studied these same SNPs in African Americans and Hispanics with limited numbers of cases and controls (70 cases vs. 90 controls and 61 cases vs. 90 controls, respectively). Although, the numbers of subjects examined in these two populations were small, the SNPs rs7764491 and rs7763822 showed a consistently strong association with anti-topo I positive SSc in both African Americans ($p=9.05 \times 10^{-3}$, OR=4.23, 95% CI=1.33-13.48 for both SNPs) and Hispanics (7.98×10^{-4} , OR=5.51, 95% CI=1.85-16.43 and $p=7.21 \times 10^{-4}$, OR=5.57, 95% CI=1.87-16.62, respectively) (Supplementary Table 4, Supplementary Table 5).

Discussion

For human complex diseases, such as SSc and systemic lupus erythematosus (SLE), there have been inconsistent reports of genetic associations from different study populations (e.g. *CTGF*^{11; 19}, *PTPN22*^{6; 20-22} and, *TGF-beta*^{10; 23; 24}). Our findings of SSc-associated HLA-DPB1 and -DPB2 on the basis of autoantibodies, represent the first replicable report in Asians, Caucasians, African-Americans and Hispanics. These complementary studies in four independent populations provide strong support for these identified genetic makers to confer susceptibility to subgroups of SSc patients. HLA-DPB1, located centromeric to other HLA class II molecules, shows relatively low linkage disequilibrium with other extended MHC haplotypes²⁵. Although it was not studied as extensively as HLA-A, -B, -C or -DR, it has similar antigen-presentation function to activate CD4+ T cells²⁶. Its genetic polymorphisms have been found to be associated with chronic berylliosis²⁷, graft-vs-host disease²⁸, juvenile rheumatoid arthritis²⁹, insulin dependent diabetes mellitus³⁰ and sarcoidosis³¹. Some studies have suggested the possible roles of HLA-DPB1 in SSc, in the context of HLA-A, B, C and DR molecules³²⁻³⁴. However, the results of our study suggest that HLA-DPB1 may be the most important susceptible gene to SSc, especially to those patients with auto-antibodies to topo-1.

Our studies indicate that sub-classification and population origin may be two critical factors in identifying genetic susceptibility markers for SSc. Such is evidenced in our lack of association in Caucasian SSc with any of the 5 SNPs found in the Korean GWAS until we took into account those subgroups defined by clinically diffuse and limited forms, but especially by specific autoantibody status (anti-topo I and anti-centromere positives). In addition, this notion may also explain previous inconsistent reports of SSc associated genes in different populations, as well as the fact that these genes were not identified in our GWAS of Koreans.

Importantly, the genetic differentiations of SSc with distinctive serological and clinical features in our studies suggest that SSc should not be considered as a single disease. While SSc, like other human complex diseases, is currently incurable, sub-classification of SSc on the basis of genetic polymorphisms for disease susceptibility may provide a new dimension for exploring pathogenesis and treatment of this disease. Our results strongly indicate that sub-classification of SSc on the basis of autoantibodies against topo I and centromeric proteins is important in defining disease susceptibility genes in this heterogeneous disease.

Keywords: Systemic sclerosis, Genome wide association study, HLA-DPB1,
Anti-topoisomerase I antibody

Acknowledgements

This study was supported by Korea Health 21 R&D Project, Ministry of Health, Welfare & Family Affairs, R.O.K. (AO30001); NIH/NIAMS P50 AR054144, NO1-AR02251 and UL1RR024148, Department of the Army, Medical Research Acquisition Activity: PR064803 and PR064851. This work cannot be accomplished without the generous provision of GWAS data and DNAs for healthy Koreans from Korean Center for Disease Control. We also thank Hua Dong for her valuable help in statistical analysis

References

1. Medsger, T.A., Jr. (2000). Arthritis and Allied Conditions. In Systemic sclerosis (scleroderma): clinical aspects W.J. Koopman, ed. (Philadelphia, Lippincott Williams & Wilkins), p 1590.
2. Bunn, C.C., and Black, C.M. (1999). Systemic sclerosis: an autoantibody mosaic. Clin Exp Immunol 117, 207-208.
3. Jarzabek-Chorzelska, M., Blaszczyk, M., Jablonska, S., Chorzelski, T., Kumar, V., and Beutner, E.H. (1986). Scl 70 antibody--a specific marker of systemic sclerosis. Br J Dermatol 115, 393-401.
4. Moroi, Y., Peebles, C., Fritzler, M.J., Steigerwald, J., and Tan, E.M. (1980). Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci U S A 77, 1627-1631.
5. Arnett, F.C. (1995). HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev Immunol 12, 107-128.
6. Gourh, P., Tan, F.K., Assassi, S., Ahn, C.W., McNearney, T.A., Fischbach, M., Arnett, F.C., and Mayes, M.D. (2006). Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis. Arthritis Rheum 54, 3945-3953.
7. Alkassab, F., Gourh, P., Tan, F.K., McNearney, T., Fischbach, M., Ahn, C., Arnett, F.C., and Mayes, M.D. (2007). An allograft inflammatory factor 1 (AIF1) single nucleotide polymorphism (SNP) is associated with anticentromere antibody positive systemic sclerosis. Rheumatology (Oxford) 46, 1248-1251.
8. Tulusso, B., Fabris, M., Caporali, R., Cuomo, G., Isola, M., Soldano, F., Montecucco, C., Valentini, G., and Ferraccioli, G. (2005). -238 and +489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis. Immunol Lett 96, 103-108.
9. Hudson, L.L., Silver, R.M., and Pandey, J.P. (2004). Ethnic differences in cytotoxic T lymphocyte associated antigen 4 genotype associations with systemic sclerosis. J Rheumatol 31, 85-87.
10. Crilly, A., Hamilton, J., Clark, C.J., Jardine, A., and Madhok, R. (2002). Analysis of transforming growth factor beta1 gene polymorphisms in patients with systemic sclerosis. Ann Rheum Dis 61, 678-681.
11. Fonseca, C., Lindahl, G.E., Ponticos, M., Sestini, P., Renzoni, E.A., Holmes, A.M., Spagnolo, P., Pantelidis, P., Leoni, P., McHugh, N., et al. (2007). A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 357, 1210-1220.
12. Chiffot, H., Fautrel, B., Sordet, C., Chatelus, E., and Sibilia, J. (2008). Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 37, 223-235.
13. Mayes, M.D., Lacey, J.V., Jr., Beebe-Dimmer, J., Gillespie, B.W., Cooper, B., Laing, T.J., and Schottenfeld, D. (2003). Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48, 2246-2255.

14. (1980). Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. *Arthritis Rheum* 23, 581-590.
15. Frazer, K.A., Ballinger, D.G., Cox, D.R., Hinds, D.A., Stuve, L.L., Gibbs, R.A., Belmont, J.W., Boudreau, A., Hardenbol, P., Leal, S.M., et al. (2007). A second generation human haplotype map of over 3.1 million SNPs. *Nature* 449, 851-861.
16. Barrett, J.C., Fry, B., Maller, J., and Daly, M.J. (2005). Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* 21, 263-265.
17. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J., et al. (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 81, 559-575.
18. Thomas, D.C., and Clayton, D.G. (2004). Betting odds and genetic associations. *J Natl Cancer Inst* 96, 421-423.
19. Rueda, B., Simeon, C., Hesselstrand, R., Herrick, A., Worthington, J., Ortego-Centeno, N., Riemekasten, G., Fonollosa, V., Vonk, M.C., van den Hoogen, F.H., et al. (2008). A large multicenter analysis of CTGF -945 promoter polymorphism does not confirm association with Systemic Sclerosis susceptibility or phenotype. *Ann Rheum Dis*.
20. Kyogoku, C., Langefeld, C.D., Ortmann, W.A., Lee, A., Selby, S., Carlton, V.E., Chang, M., Ramos, P., Baechler, E.C., Batliwalla, F.M., et al. (2004). Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. *Am J Hum Genet* 75, 504-507.
21. Viken, M.K., Amundsen, S.S., Kvien, T.K., Boberg, K.M., Gilboe, I.M., Lilleby, V., Sollid, L.M., Forre, O.T., Thorsby, E., Smerdel, A., et al. (2005). Association analysis of the 1858C>T polymorphism in the PTPN22 gene in juvenile idiopathic arthritis and other autoimmune diseases. *Genes Immun* 6, 271-273.
22. Wipff, J., Allanore, Y., Kahan, A., Meyer, O., Mouthon, L., Guillevin, L., Pierlot, C., Glikmans, E., Bardin, T., Boileau, C., et al. (2006). Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population. *Ann Rheum Dis* 65, 1230-1232.
23. Lee, E.B., Kim, J.Y., Lee, Y.J., Abdallah, A., Lympny, P., and Song, Y.W. (2004). Transforming growth factor-beta1 polymorphisms in Korean patients with systemic sclerosis. *Tissue Antigens* 63, 491-495.
24. Sugiura, Y., Banno, S., Matsumoto, Y., Niimi, T., Yoshinouchi, T., Hayami, Y., Naniwa, T., and Ueda, R. (2003). Transforming growth factor beta1 gene polymorphism in patients with systemic sclerosis. *J Rheumatol* 30, 1520-1523.
25. Begovich, A.B., McClure, G.R., Suraj, V.C., Helmuth, R.C., Fildes, N., Bugawan, T.L., Erlich, H.A., and Klitz, W. (1992). Polymorphism, recombination, and linkage disequilibrium within the HLA class II region. *J Immunol* 148, 249-258.
26. McCanlies, E.C., Kreiss, K., Andrew, M., and Weston, A. (2003). HLA-DPB1 and chronic beryllium disease: a HuGE review. *Am J Epidemiol* 157, 388-398.
27. Richeldi, L., Sorrentino, R., and Saltini, C. (1993). HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. *Science* 262, 242-244.

28. Shaw, B.E., Potter, M.N., Mayor, N.P., Pay, A.L., Smith, C., Goldman, J.M., Prentice, H.G., Marsh, S.G., and Madrigal, J.A. (2003). The degree of matching at HLA-DPB1 predicts for acute graft-versus-host disease and disease relapse following haematopoietic stem cell transplantation. *Bone Marrow Transplant* 31, 1001-1008.
29. Begovich, A.B., Bugawan, T.L., Nepom, B.S., Klitz, W., Nepom, G.T., and Erlich, H.A. (1989). A specific HLA-DP beta allele is associated with pauciarticular juvenile rheumatoid arthritis but not adult rheumatoid arthritis. *Proc Natl Acad Sci U S A* 86, 9489-9493.
30. Cruz, T.D., Valdes, A.M., Santiago, A., Frazer de Llado, T., Raffel, L.J., Zeidler, A., Rotter, J.I., Erlich, H.A., Rewers, M., Bugawan, T., et al. (2004). DPB1 alleles are associated with type 1 diabetes susceptibility in multiple ethnic groups. *Diabetes* 53, 2158-2163.
31. Lympny, P.A., Petrek, M., Southcott, A.M., Newman Taylor, A.J., Welsh, K.I., and du Bois, R.M. (1996). HLA-DPB polymorphisms: Glu 69 association with sarcoidosis. *Eur J Immunogenet* 23, 353-359.
32. Kuwana, M., Inoko, H., Kameda, H., Nojima, T., Sato, S., Nakamura, K., Ogasawara, T., Hirakata, M., Ohosone, Y., Kaburaki, J., et al. (1999). Association of human leukocyte antigen class II genes with autoantibody profiles, but not with disease susceptibility in Japanese patients with systemic sclerosis. *Intern Med* 38, 336-344.
33. Tikly, M., Rands, A., McHugh, N., Wordsworth, P., and Welsh, K. (2004). Human leukocyte antigen class II associations with systemic sclerosis in South Africans. *Tissue Antigens* 63, 487-490.
34. Reveille, J.D., Brady, J., MacLeod-St Clair, M., and Durban, E. (1992). HLA-DPB1 alleles and autoantibody subsets in systemic lupus erythematosus, Sjogren's syndrome and progressive systemic sclerosis: a question of disease relevance. *Tissue Antigens* 40, 45-48.


Figures legends

Figure 1. Identification of the major locus associated with SSc in genome wide scan of Koreans. A total of 440,734 SNPs were evaluated in 133 patients with SSc and 557 healthy controls. A) Quantile-quantile plot compares the distributions of observed P-values with expected null P values. B) Distribution of $-\text{Log}_{10}$ P values are plotted against chromosomes.

Figure 2. HLA-DPB as a culprit region for susceptibility to systemic sclerosis. – Log_{10} P values are depicted around the HLA-DPB region. All genes in the region are also displayed above the linkage disequilibrium (LD) map. LD between pairs of SNPs is depicted with linkage blocks in which bright red block represents disequilibrium coefficient (D') of 1.0 and white block D' of 0.0. Orange bar above the LD map represents high LD SNPs which show significant association ($r^2 > 0.8$) with culprit SNPs.

Figure 1

a



b




Figure 2




Table 1. Association of SNPs rs3128930, rs7764491 and rs3128965 with Korean SSc patients with and without autoantibodies to DNA topoisomerase I and centromere protein.

Alleles (Mnino allele)	Systemic sclerosis				Controls	
	Anti-topoisomerase I Ab ^b		Anti-centromere Ab		Total	
	(+) (n=79)	(-) (n=48)	(+) (n=16)	(-) (n=117)	(n=133)	(n=557)
rs3128930 (A)						
Frequency	0.47	0.15	0.13	0.39	0.36	0.15
P-value ^a	1.70x10 ⁻²²	0.93	0.705	2.38x10 ⁻¹⁷	7.84x10 ⁻¹⁵	-
OR (95% CI) ^a	5.15(3.62-7.34)	0.97 (0.54-1.76)	0.82(0.28-2.35)	3.63(2.66-4.95)	3.17(2.35-4.28)	-
rs7764491 (C)						
Frequency	0.21	0.073	0.063	0.17	0.16	0.057
P-value ^a	1.18x10 ⁻¹¹	0.51	0.886	2.13x10 ⁻⁹	2.13x10 ⁻⁸	-
OR (95% CI) ^a	4.40(2.78-6.98)	1.31(0.58-2.95)	1.11(0.26-4.76)	3.44(2.25-5.26)	3.13(2.06-4.74)	-
rs3128965 (A)						
Frequency	0.26	0.073	0.063	0.21	0.19	0.093
P-value ^a	7.78x10 ⁻¹⁰	0.506	0.553	1.44x10 ⁻⁷	2.29x10 ⁻⁶	-
OR(95% CI) ^a	3.40(2.26-5.12)	0.76 (0.34-1.69)	0.65(0.15-2.75)	2.64(1.82-3.83)	2.36(1.64-3.40)	-

a. Each subset versus controls b. Missing information of anti-topoisomerase I antibody status in 6 patients; Ab, antibody; CI, confidence interval

Table 2. Association of HLA-DPB1 allelic subtypes with systemic sclerosis in Koreans.

HLA alleles	Systemic sclerosis				Total	Controls
	Anti-topoisomerase-I Ab ^b		Anti-centromere Ab			
	(+)	(-)	(+)	(-)		
	(n=82)	(n=49)	(n=16)	(n=121)	(n=137)	(n=548)
*1301						
Frequency	0.21	0.05	0.031	0.17	0.15	0.055
P-value ^a	4.05x10 ⁻¹²	0.876	0.562	3.25x10 ⁻⁹	7.61x10 ⁻⁸	-
OR (95% CI) ^a	4.52(2.86-7.14)	0.93(0.36-2.37)	0.56(0.074-4.15)	3.42(2.23-5.24)	3.04(1.99-4.63)	-
*0901						
Frequency	0.12	0.01	0.031	0.087	0.08	0.026
P-value ^a	2.44x10 ⁻⁸	0.325	0.868	7.55x10 ⁻⁶	2.55x10 ⁻⁵	-
OR (95% CI) ^a	4.82(2.64-8.82)	0.38(0.05-2.82)	1.19(0.16-8.99)	3.50(1.96-6.24)	3.21(1.82-5.69)	-
*030101						
Frequency	0.1	0.02	0.031	0.083	0.077	0.043
P-value ^a	9.47x10 ⁻⁴	0.283	0.748	0.01	0.0214	-
OR (95% CI) ^a	2.58(1.44-4.61)	0.47(0.11-1.94)	0.72(0.096-5.39)	2.01(1.17-3.46)	1.85(1.09-3.16)	-

a. Each subset versus controls b. Missing information of anti-topoisomerase I antibody

status in 6 patients; Ab, antibody; CI, confidence interval

Table 3. Association of SNPs of HLA-*DPB1* and -*DPB2* with systemic sclerosis in Caucasians.

Alleles (Minor allele)	Systemic sclerosis ^b				Controls	
	Anti-topoisomerase I Ab		Anti-centromere Ab			
	(+)	(-)	(+)	(-)		
	(n=183)	(n=917)	(n=316)	(n=784)	(n=2,731)	
rs3128930 (A)						
Frequency	0.31	0.28	0.3	0.28	0.29	0.27
P-value ^a	0.117	0.295	0.0564	0.47	0.14	-
OR (95% CI) ^a	1.20(0.95-1.51)	1.01(0.95-1.20)	1.19(1.00-1.43)	1.05(0.92-1.19)	1.09(0.97-1.21)	-
rs7764491 (C)						
Frequency	0.14	0.03	0.025	0.058	0.049	0.043
P-value ^a	4.84x10 ⁻¹⁶	0.0175	0.036	0.0155	0.29	-
OR (95% CI) ^a	3.56(2.57-4.94)	0.70(0.52-0.94)	0.58(0.35-0.97)	1.36(1.06-1.75)	1.14(0.90-1.44)	-
rs7763822 (T)						
Frequency	0.14	0.031	0.024	0.059	0.049	0.043
P-value ^a	7.58x10 ⁻¹⁷	0.0214	0.0227	0.0076	0.236	-
OR (95% CI) ^a	3.65(2.64-5.04)	0.71(0.53-0.95)	0.55(0.32-0.93)	1.40(1.09-1.80)	1.15(0.91-1.46)	-
rs3128965 (A)						
Frequency	0.14	0.19	0.25	0.16	0.18	0.18
P-value ^a	0.0237	0.394	3.20x10 ⁻⁵	0.01	0.99	-
OR (95% CI) ^a	0.70(0.52-0.96)	1.06(0.93-1.21)	1.50(1.24-1.82)	0.82(0.70-0.95)	1.00 (0.88-1.14)	-
rs3117230 (G)						
Frequency	0.17	0.26	0.29	0.22	0.24	0.24
P-value ^a	0.00765	0.055	1.12x10 ⁻³	0.32	0.42	-
OR (95% CI) ^a	0.69(0.52-0.91)	1.13(1.00-1.28)	1.36(1.13-1.63)	0.93(0.81-1.07)	1.05(0.93-1.18)	-

a. Each subset versus controls b. Missing information of autoantibody status in 6

patients; Ab, antibody; CI confidence interval

Supplementary Table 1. Association of rs312930, rs7764491 and rs3128965 with subsets of systemic sclerosis in Koreans.

SNPs	Systemic sclerosis				Controls
(Minor allele)	Skin subset		Limited/Cent+ (n=12)	Diffuse/Topo+ (n=45)	
	Limited	Diffuse			
	(n=67)	(n=66)			
rs3128930 (A)					
Frequency	0.33	0.39	0.13	0.49	0.15
P-value ^a	1.67x10 ⁻⁷	1.15x10 ⁻¹¹	0.742	3.33x10 ⁻¹⁶	
OR (95% CI) ^a	2.79(1.88-4.15)	3.59(2.44-5.29)	0.81(0.24-2.76)	5.46(3.50-8.51)	
rs7764491(C)					
Frequency	0.11	0.2	0.083	0.26	0.057
P-value ^a	0.0123	5.28x10 ⁻¹⁰	0.576	1.77x10 ⁻¹²	
OR (95% CI) ^a	2.10(1.16-3.81)	4.29(2.62-7.03)	1.52(0.35-6.59)	5.73(3.35-9.80)	
rs3128965 (A)					
Frequency	0.22	0.17	0.042	0.22	0.093
P-value ^a	1.29x10 ⁻⁵	3.68x10 ⁻³	0.387	1.09x10 ⁻⁴	
OR (95% CI) ^a	2.68(1.70-4.24)	2.05(1.25-3.36)	0.42(0.056-3.16)	2.78(1.62-4.74)	

a. Each subset versus controls; Ab, antibody; Cent, anti-centromere antibody; CI confidence interval; Topo, anti-topoisomerase I antibody

Supplementary Table 2. Association of SNPs of HLA-DPB1 and –DPB2 with subsets of systemic sclerosis in Caucasians

SNPs (Minor allele)	Systemic sclerosis				Controls (n=2,731)
	Skin subset		Limited/Cent+ (n=277)	Diffuse/Topo+ (n=88)	
	Limited (n=654)	Diffuse (n=419)			
rs3128930 (A)					
Frequency	0.28	0.28	0.31	0.33	0.27
P-value ^a	0.238	0.376	0.041	0.072	-
OR (95% CI) ^a	1.08(0.94-1.24)	1.08(0.91-1.27)	1.22(1.01-1.48)	1.34(0.97-1.85)	-
rs7764491(C)					
Frequency	0.04	0.62	0.025	0.14	0.043
P-value ^a	0.647	0.014	0.0485	4.76x10 ⁻¹⁰	-
OR (95% CI) ^a	0.93(0.68-1.27)	1.47(1.08-2.02)	0.58(0.34-1.00)	3.73(2.39-5.81)	-
rs7763822(T)					
Frequency	0.04	0.064	0.024	0.15	0.043
P-value ^a	0.632	0.007	0.0299	3.99x10 ⁻¹¹	-
OR (95% CI) ^a	0.93(0.68-1.26)	1.52(1.12-2.07)	0.54(0.31-0.95)	3.93(2.54-6.08)	-
rs3128965 (A)					
Frequency	0.2	0.16	0.26	0.13	0.18
P-value ^a	0.22	0.0765	1.71x10 ⁻⁵	0.047	-
OR (95% CI) ^a	1.1(0.94-1.28)	0.84(0.69-1.02)	1.56(1.27-1.90)	0.63(0.40-1.00)	-
rs3117230(G)					
Frequency	0.26	0.21	0.3	0.15	0.24
P-value ^a	0.046	0.15	6.9x10 ⁻⁴	6.08x10 ⁻³	-
OR (95% CI) ^a	1.15(1.00-1.33)	0.88(0.73-1.04)	1.40(1.15-1.70)	0.55(0.36-0.84)	-

a. Each subset versus controls; Ab, antibody; Cent, anti-centromere antibody; CI

confidence interval; Topo, anti-topoisomerase I antibody

Supplementary Table 3. Comparison of Caucasian SSc patients with and without autoantibodies to topo I or centromere protein.

Alleles (Minor allele)	Anti-topoisomerase I Ab		p-values ^a OR(95% CI)	Anti-centromere Ab		p-values ^b OR(95% CI)
	(+)	(-)		(+)	(-)	
	(n=183)	(n=917)		(n=316)	(n=784)	
rs3128930 (A)						
Frequency	0.31	0.28	0.33 1.13(0.88-1.44)	0.30	0.28	0.212 1.14(0.93-1.39)
rs7764491 (C)						
Frequency	0.14	0.030	2.86x10 ⁻¹⁸ 5.11(3.42-7.63)	0.025	0.058	1.5x10 ⁻³ 0.43(0.25-0.73)
rs7763822 (T)						
Frequency	0.14	0.031	8.61x10 ⁻¹⁹ 5.12(3.46-7.68)	0.024	0.059	5.60x10 ⁻⁴ 0.39(0.22-0.68)
rs3128965 (A)						
Frequency	0.14	0.19	0.0116 0.66(0.48-0.91)	0.25	0.16	1.07x10 ⁻⁷ 1.84(1.46-2.30)
rs3117230 (G)						
Frequency	0.17	0.26	7.35x10 ⁻⁴ 0.61(0.45-0.81)	0.29	0.22	4.77x10 ⁻⁴ 1.45(1.18-1.79)

a. Comparison between anti-topoisomerase I antibody + and -; b. Comparison between anti-centromere antibody + and -.

Supplementary Table 4. Association of the SNPs with SSc patients with and without autoantibodies to DNA topoisomerase I and centromere protein in African Americans .

SNPs	Systemic sclerosis					Controls
(Minor allele)	Anti-topoisomerase-I Ab		Anti-centromere Ab		Total	
	(+)	(-)	(+)	(-)		
	(n=9)	(n=61)	(n=5)	(n=65)	(n=70)	(n=90)
rs3128930 (A)						
Frequency	0.5	0.55	0.3	0.56	0.54	0.44
P-value ^a	0.615	0.0588	0.391	0.0325	0.0637	-
OR (95% CI) ^a	1.28(0.49-3.38)	1.56(0.98-2.48)	0.55(0.14-2.19)	1.64(1.04-2.59)	1.52(0.98-2.38)	-
rs7764491(C)						
Frequency	0.28	0.14	0.1	0.16	0.16	0.083
P-value ^a	9.05x10 ⁻³	0.109	0.853	0.0297	0.036	-
OR (95% CI) ^a	4.23(1.33-13.48)	1.82(0.87-3.79)	1.22(0.14-10.31)	2.16(1.07-4.37)	2.09(1.04-4.19)	-
rs7763822(T)						
Frequency	0.28	0.14	0.1	0.16	0.16	0.083
P-value ^a	9.05x10 ⁻³	0.121	0.853	0.0339	0.0405	-
OR (95% CI) ^a	4.23(1.33-13.48)	1.78(0.85-3.72)	1.22(0.14-10.31)	2.12(1.05-4.29)	2.05(1.02-4.12)	-
rs3128965 (A)						
Frequency	0	0.067	0	0.063	0.058	0.068
P-value ^a	0.253	0.959	0.393	0.844	0.713	-
OR (95% CI) ^a	-	0.98(0.39-2.47)	-	0.91(0.36-2.30)	0.84(0.33-2.12)	-
rs3117230(G)						
Frequency	0.28	0.41	0.2	0.41	0.39	0.38
P-value ^a	0.383	0.628	0.247	0.649	0.844	-
OR (95% CI) ^a	0.62(0.21-1.82)	1.12(0.70-1.80)	0.40(0.83-1.96)	1.11(0.70-1.77)	1.05(0.66-1.65)	-

a.Each subset versus controls; Ab, antibody; CI confidence interval

Supplementary Table 5. Association of the SNPs with SSc patients with and without autoantibodies to DNA topoisomerase I and centromere protein in Hispanics.

SNPs	Systemic sclerosis				Controls	
(Minor allele)	Anti-topoisomerase-I Ab		Anti-centromere Ab		Total	
	(+)	(-)	(+)	(-)		
	(n=17)	(n=44)	(n=12)	(n=49)	(n=61)	(n=90)
rs3128930(A)						
Frequency	0.29	0.38	0.29	0.37	0.35	0.24
P-value ^a	0.493	0.02	0.571	0.0236	0.0324	-
OR(95% CI) ^a	1.33(0.59-3.00)	1.91(1.10-3.33)	1.31(0.51-3.38)	1.85(1.01-3.17)	1.74(1.05-2.89)	-
rs7764491(C)						
Frequency	0.21	0.034	0	0.1	0.082	0.045
P-value ^a	7.98x10 ⁻⁴	0.676	0.289	0.066	0.185	-
OR (95% CI) ^a	5.51(1.85-16.43)	0.75(0.19-2.90)	-	2.42(0.92-6.34)	1.90(0.73-4.95)	-
rs7763822(T)						
Frequency	0.21	0.034	0	0.01	0.082	0.044
P-value ^a	7.21x10 ⁻⁴	0.688	0.292	0.0623	0.177	-
OR (95% CI) ^a	5.57(1.87-16.62)	0.76(0.20-2.93)	-	2.44(0.93-6.41)	1.92(0.74-5.01)	-
rs3128965(A)						
Frequency	0.029	0.2	0.25	0.13	0.16	0.16
P-value ^a	0.0429	0.381	0.278	0.532	0.904	-
OR (95% CI) ^a	0.16(0.020-1.20)	1.34(0.70-2.59)	1.73(0.63-4.77)	0.80(0.39-1.62)	0.96(0.51-1.82)	-
rs3117230(G)						
Frequency	0.088	0.35	0.25	0.29	0.28	0.21
P-value ^a	0.0972	0.013	0.656	0.159	0.173	-
OR (95% CI) ^a	0.36(0.11-1.26)	2.04(1.16-3.61)	1.25(0.46-3.38)	1.50(0.85-2.65)	1.45(0.85-2.48)	-

a.Each subset versus controls; Ab, antibody; CI confidence interval



Attenuation of fibrosis in vitro and in vivo with Sparc siRNA

Journal:	<i>Arthritis and Rheumatism</i>
Manuscript ID:	draft
Wiley - Manuscript type:	Full Length
Date Submitted by the Author:	
Complete List of Authors:	Wang, Jiu-Cun; University of Texas Health Sciences Center at Houston, Internal Medicine; School of Life Sciences, Fudan University, State Key Laboratory of Genetic Engineering and MOE Key Laboratory of Contemporary Anthropology; Fudan University, Institute of Rheumatology, Immunology and Allergy Lai, Syeling; Baylor College of Medicine, Pathology Guo, Xinjian; University of Texas Health Sciences Center at Houston, Internal Medicine Zhang, Xuefeng; University of Texas Health Sciences Center at Houston, Internal Medicine de Crombrughe, Benoit; MD. Anderson Cancer Center, University of Texas, 5. Department of Molecular Genetics Arnett, Frank; University of Texas Health Sciences Center at Houston, Internal Medicine Zhou, Xiaodong; University of Texas Health Sciences Center at Houston, Internal Medicine
Keywords:	Mouse, Pulmonary, Systemic sclerosis



Attenuation of fibrosis *in vitro* and *in vivo* with Sparc siRNA

JIU-CUN WANG,^{1,2,3} SYELING LIAO,⁴ XINJIAN GUO,¹ XUEFENG ZHANG,¹ BENOIT DE CROMBIE,⁵ JGGHE
FRANK. C. ARNETT,¹ XIAODONG ZHOU¹

1. DIVISION OF RHEUMATOLOGY AND CLINICAL IMMUNOGENETICS, DEPARTMENT OF INTERNAL MEDICINE, THE UNIVERSITY OF TEXAS MEDICAL SCHOOL AT HOUSTON
2. STATE KEY LABORATORY OF GENETIC ENGINEERING AND MOE KEY LABORATORY OF ANTHROPOLOGY, SCHOOL OF LIFE SCIENCES, FUDAN UNIVERSITY, CHINA
3. INSTITUTE OF RHEUMATOLOGY, IMMUNOLOGY AND ALLERGY, FUDAN UNIVERSITY, CHINA
4. DEPARTMENT OF PATHOLOGY, BAYLOR COLLEGE OF MEDICINE,
5. DEPARTMENT OF MOLECULAR GENETICS, MD. ANDERSON CANCER CENTER, UNIVERSITY OF TEXAS MD. ANDERSON CANCER CENTER, HOUSTON, TEXAS

Correspondence should be addressed to Xiaodong Zhou

Department of Internal Medicine

Division of Rheumatology and Clinical Immunogenetics

University of Texas Medical School at Houston

Phone: 713-500-6088

Fax: 713-500-0580

ABSTRACT

OBJECTIVE: SPARC (SECRETED PROTEIN, ACIDIC AND RICH IN CYSTEINE) IS A MATRICEC
WHICH ALONG WITH OTHER EXTRACELLULAR MATRIX (ECM) COMPONENTS INCLUDING COLLAGEN
OVER-EXPRESSED IN FIBROTIC DISEASES. THE PURPOSE OF THIS STUDY WAS TO EXAMINE WHETHER
SPARC CAN REGULATE COLLAGEN EXPRESSION *in vivo*, AND SUBSEQUENTLY ATTENUATE FIBROSIS
STIMULATION BY BLEOMYCIN IN MOUSE SKIN AND LUNGS.

METHODS: *in vitro* STUDIES, SKIN FIBROBLASTS OBTAINED FROM K14-CRE-ERT2 (K14-
CRE-ER) WERE TRANSFECTED WITH SPARC siRNA. GENE AND PROTEIN EXPRESSIONS OF TGF-
CTGF WERE EXAMINED BY REAL-TIME RT-PCR AND WESTERN BLOTTING, RESPECTIVELY. *In vivo*,
C57BL/6 MICE WERE INDUCED FOR SKIN AND LUNG FIBROSIS BY BLEOMYCIN AND FOLLOWED BY
TREATMENT THROUGH SUBCUTANEOUS INJECTION AND INTRATRACHEAL INSTILLATION.
PATHOLOGICAL CHANGES OF SKIN AND LUNGS WERE ASSESSED BY HEMATOXYLIN AND EOSIN
TRICHROME STAINS. THE EXPRESSION CHANGES OF COLLAGEN IN THE TISSUES WERE ASSESSED BY
RT-PCR AND NON-CROSSLINKED FIBRILLAR COLLAGEN CONTENT ASSAYS.

RESULTS: SPARC siRNA SIGNIFICANTLY REDUCED GENE AND PROTEIN EXPRESSION OF CTGF
FIBROBLASTS OBTAINED FROM TGF- β 1^{CA} MICE THAT WAS INDUCED FOR CONSTITUTIVE
TGF- β RECEPTOR I. SKIN AND LUNG FIBROSIS INDUCED BY BLEOMYCIN WAS MARKEDLY REDUCED
WITH SPARC siRNA. THE ANTI-FIBROTIC EFFECT OF SPARC siRNA ACCOMPANIED BY AN
INHIBITION OF CTGF EXPRESSION IN THESE SAME TISSUES.

CONCLUSION: SPECIFIC INHIBITION OF SPARC EFFECTIVELY REDUCED FIBROTIC CHANGES
in vivo. SPARC INHIBITION MAY REPRESENT A POTENTIAL THERAPEUTIC APPROACH TO FIBROTIC

INTRODUCTION

FIBROSIS IS A GENERAL PATHOLOGICAL PROCESS IN WHICH EXCESSIVE DEPOSITION OF EXTRACELLULAR MATRIX (ECM) OCCURS IN THE TISSUES. IT IS CURRENTLY UNTREATABLE. ALTHOUGH THE USE OF ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE AGENTS SUCH AS COLCHICINES, METHOTREXATE, CORTICOSTEROIDS AND CYCLOPHOSPHAMIDE HAVE BEEN REPORTED, MANY OF THESE APPROACHES HAVE NOT BEEN PROVEN SUCCESSFUL (1-3). RECENTLY, SPARC (SECRETED PROTEIN, ACIDIC AND RICH IN Cysteine) A MATRICELLULAR COMPONENT OF THE ECM, HAS BEEN REPORTED AS A BIO-MARKER FOR FIBROTIC DISEASES, SUCH AS INTERSTITIAL PULMONARY FIBROSIS, RENAL INTERSTITIAL DISEASE, ATHEROSCLEROTIC LESIONS AND SCLERODERMA OR SYSTEMIC SCLEROSIS (SSC) (4-9). NOVEL EXPRESSION OF SPARC HAS BEEN OBSERVED IN AFFECTED SKIN AND CIRCULATION OF SPARC (10,11), A DEVASTATING DISEASE OF SYSTEMIC FIBROSIS, AS WELL AS IN CULTURED DERMAL CELLS OBTAINED FROM SSC SKIN (8,9).

SPARC, ALSO CALLED OSTEONECTIN OR BM-40, IS AN IMPORTANT MEDIATOR OF CELL-CELL AND CELL-MATRIX INTERACTION (12). INCREASING EVIDENCE INDICATES THAT SPARC MAY PLAY AN IMPORTANT ROLE IN FIBROSIS. IN ADDITION TO ITS HIGHER EXPRESSION LEVEL IN THE TISSUES OF FIBROTIC DISEASES, SPARC HAS SHOWN A CAPACITY TO STIMULATE THE TRANSFORMING GROWTH FACTOR β 1 (TGF- β 1) SECRETION BY HUMAN FIBROBLASTS (13). INHIBITION OF SPARC ATTENUATES THE PROFIBROTIC EFFECT OF TGF- β 1 ON EXPOSED HUMAN FIBROBLASTS (14). MOREOVER, IN ANIMAL STUDIES, SPARC-NUL MICE DISPLAY A DIMINISHED LEVEL OF PULMONARY FIBROSIS COMPARED WITH CONTROL MICE AFTER EXPOSURE TO BLEOMYCIN, AN ANTIBIOTIC WITH A PROFIBROTIC EFFECT (15). THESE OBSERVATIONS SUGGEST THAT SPARC IS A POTENTIAL BIO-TARGET FOR ANTI-FIBROTIC THERAPY. THE STUDIES DESCRIBED HERE AIMED TO EXPLORE THE EFFECT OF INHIBITION OF SPARC WITH SIRNA TO COUNTER FIBROTIC PROCESSES BOTH USING MURINE MODELS.

MATERIALS AND METHODS

Fibroblast cell lines from Tgfr1 knock-in mouse. CONSTITUTIVELY ACTIVATED TGFBR1 MURINE CELL LINES WHICH RECAPITULATED CLINICAL, HISTOLOGICAL, AND BIOCHEMICAL FEATURES OF HUMAN FIBROSIS WERE REPORTED PREVIOUSLY (16). THEY ARE TERMED Tgfr1 MICE AND HARBOR BOTH THE DNA FOR

INDUCIBLE CONSTITUTIVELY ACTIVE TGF- β 1 (TGF- β 1) MUTATION TARGETED TO THE ROSA LOCUS, AND A CRE-ER TRANSGENE DRIVEN BY FIBROBLAST-SPECIFIC PROMOTER. ADMINISTRATION OF 4-HYDROXYTAMOXIFEN (4-OHT) 2 WEEKS AFTER BIRTH ACTIVATES THE EXPRESSION OF CLOXIPROGEN-INDUCIBLE TGF- β 1 IN THE MICE (16). FIBROBLASTS WERE DERIVED FROM SKIN BIOPSY SPECIMENS OF 129/SV EVR MICE. CULTURES WERE MAINTAINED IN DMEM WITH 10% FCS AND SUPPLEMENTED WITH ANTIBIOTICS (100 U/ml PENICILLIN AND 100 U/ml STREPTOMYCIN). FIFTH-PASSAGE FIBROBLAST CELLS WERE SEEDING AT 10^5 CELLS IN 25- cm^2 FLASKS AND GROWN UNTIL CONFLUENCE. EXPERIMENTS WERE PERFORMED IN TRIPLICATES.

Transient transfection with siRNA in fibroblasts. DOUBLE-STRANDED ON-TARGETING siRNAs OF *MurK1* AND *Ctgf* WERE PURCHASED FROM DHARMACON, INC. (LAFAYETTE, CA). CORRESPONDING TARGET SEQUENCES ARE 5'- GCACCACACGUUUCUUAAGAG-3' FOR *MurK1* AND 5'- GCACCAGUGUGAAGACAUA-3' FOR *Ctgf*, RESPECTIVELY. THE CULTURE MEDIUM IN EACH FLASK WITH CONFLUENT FIBROBLASTS WAS REPLACED WITH OPTI-MEM I MEDIUM (INVITROGEN) WITHOUT FCS AND ANTIBIOTICS. THE FIBROBLASTS WERE INCUBATED FOR 24 HOURS AND THEN TRANSFECTED WITH siRNA OR CTGF siRNA IN A CONCENTRATION OF 100 NMOL/L, USING LIPID siRNA TRANSFECTION REAGENT (DHARMACON). FIBROBLASTS WITH NON-TARGETING siRNA (DHARMACON) WERE USED AS NEGATIVE CONTROLS. AFTER 24 HOURS, THE CULTURE MEDIUM WAS REPLACED WITH DMEM. CELLS TRANSFECTED WITH siRNA WERE EXAMINED AFTER 72 HOURS OF TRANSFECTION AND PROTEIN EXPRESSION ANALYSIS. THE EXPERIMENTS WERE PERFORMED IN TRIPLICATES.

Animal models of fibrosis. C57BL/6 MICE OF ABOUT 20 GRAMS WERE PURCHASED FROM JACKSON LABORATORY (BAR HARBOR, MAINE). BLEOMYCIN FROM TEVA PARENTERAL MEDICATIONS (HOLLYWOOD, CA) WAS DISSOLVED IN SALINE AND USED IN THE MICE AT A CONCENTRATION OF 3.5 U/ml. PULMONARY FIBROSIS WAS INDUCED IN THESE MICE WITH ONCE INTRATRACHEAL INSTILLATION OF BLEOMYCIN. FOR DERMAL FIBROSIS, FEMALE C57BL/6 MICE AT 6 WEEKS (WEIGHING ABOUT 20 G) WERE TREATED FOR 4 WEEKS WITH LOCAL SUBCUTANEOUS INJECTION OF BLEOMYCIN IN THE SHAVED LOWER BACK. FOUR MICE WERE USED IN EACH GROUP. THE ANIMAL PROTOCOLS WERE APPROVED BY THE CENTER FOR ANIMAL MEDICINE AND CARE IN THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON AND THE INSTITUTIONAL ANIMAL USE AND CARE COMMITTEE OF M.D. ANDERSON CANCER CENTER.

Administration of siRNAs *in vivo*. FOR PULMONARY FIBROSIS, siRNA FOR *MurK1* OR *Ctgf* (DHARMACON), MIXED WITH LIPID siRNA TRANSFECTION REAGENT, WAS INJECTED INTO THE PLEURAL SPACE OF MICE.

ADMINISTRATED INTRATRACHEALLY ON DAYS 0, 5, 12 AFTER BLEOMYCIN TREATMENT. ALL THE MICE WERE SACRIFICED ON DAY 23 AFTER ANESTHESIA, AND THE LUNG SAMPLES WERE COLLECTED. THE LUNGS WERE FIXED IN 4% FORMALIN AND USED FOR FURTHER HISTOLOGICAL ANALYSIS. THE RIGHT LUNGS WERE CUT INTO 2 PIECES AND DIVIDED INTO 2 PARTS, ONE FOR RNA EXTRACTION AND ONE FOR COLLAGEN DEPOSITION. FOR DERMAL FIBROSIS, THE ABOVE SIRNAS WERE INJECTED INTO THE SAME AREA AS THAT OF THE LUNGS. AFTER BLEOMYCIN TREATMENT AND CONTINUED FOR 4 WEEKS. THE MICE WERE SACRIFICED ON DAY 23. SKIN SAMPLES WERE COLLECTED. SALINE WAS USED AS A CONTROL IN BOTH FIBROSIS STUDIES.

Determination of gene expression by quantitative RT-PCR. TOTAL RNA FROM EACH CELL LINE WAS EXTRACTED FROM THE CULTURED FIBROBLASTS USING RNEASY MINI KIT (QIAGEN). FOR MICE LUNG AND SKIN TISSUES, THE MINCED SAMPLES WERE HOMOGENIZED IN LYSSES SOLUTION (SIGMA-ALDRICH, ST. LOUIS, MO) WITH A BLENDER. THEN TOTAL RNA WAS EXTRACTED USING GENELUTE™ M (SIGMA-ALDRICH). RNA MINIPREP KIT (SIGMA-ALDRICH). COMPLEMENTARY DNA (CDNA) WAS SYNTHESIZED USING MULTISCRIBE™ REVERSE TRANSCRIPTASE (APPLIED BIOSYSTEMS). QUANTITATIVE REAL-TIME PCR WAS PERFORMED USING AN ABI 7900 SEQUENCE DETECTOR SYSTEM (APPLIED BIOSYSTEMS, FOSTER CITY, CA). THE SPECIFIC PRIMERS AND PROBES FOR COL1A2, CTGF, AND SPARC WERE PURCHASED FROM THE ASSAYS-ON-DEMAND PRODUCT LINE (APPLIED BIOSYSTEMS). SYNTHESIZED CDNA WAS ASSAYED WITH PRIMERS/PROBES IN 2 × TAQMAN UNIVERSAL PCR BUFFER AND THEN ASSAYED ON THE ABI 7900 SEQUENCE DETECTOR. THE DATA OBTAINED FROM THE ASSAYS WERE ANALYZED WITH THE 2^{-ΔΔCT} METHOD (APPLIED BIOSYSTEMS). THE EXPRESSION LEVEL OF EACH GENE IN EACH SAMPLE WAS NORMALIZED TO *Gapdh* TRANSCRIPT LEVEL.

Western blot analysis. THE CELLULAR LYSATES EXTRACTED FROM THE CULTURED FIBROBLASTS WERE USED FOR PROTEIN ASSAYS. THE PROTEIN CONCENTRATION WAS DETERMINED BY A SPECIFIC PROTEIN ASSAY KIT (BRADFORD PROTEIN ASSAY KIT (BIO-RAD LABORATORIES, HERCULES, CA). EQUAL AMOUNTS OF EACH SAMPLE WERE SUBJECTED TO SODIUM DODECYL SULFATE-POLYACRYLAMIDE GEL ELECTROPHORESIS. RESOLVED PROTEINS WERE TRANSFERRED ONTO PVDF MEMBRANES AND INCUBATED WITH PRIMARY ANTIBODIES, INCLUDING ANTI-TYPE I COLLAGEN ANTIBODY (BIODESIGN INTERNATIONAL, FARMERSVILLE, OH), ANTI-CTGF ANTIBODY (GENETEX INC, SAN ANTONIO, TX), AND ANTI-SPARC ANTIBODY (R&D SYSTEMS, MINNEAPOLIS, MN). MOUSE ANTI-HUMAN CTGF ANTIBODY (ALEXIS BIOCHEMICALS, SAN DIEGO, CA) WAS USED AS A POSITIVE CONTROL. THE SECONDARY ANTIBODY WAS PEROXIDASE-CONJUGATED ANTI-RABBIT, AN

IGG. SPECIFIC PROTEINS WERE DETECTED BY CHEMILUMINESCENCE USING AN ENHANCED SYSTEM (AMERSHAM, PISCATAWAY, NJ). THE INTENSITY OF THE BANDS WAS QUANTIFIED USING IMAGEJ SOFTWARE (MOLECULAR DYNAMICS, SUNNYVALE, CA).

Determination of collagen content. NON-CROSSLINKED FIBRILLAR COLLAGEN IN LUNG AND SKIN SAMPLES WAS MEASURED USING THE SIRCOL COLORIMETRIC ASSAY (BIOCOLOR, CAMBRIDGE, UK). TISSUES WERE HOMOGENIZED IN 0.5M ACETIC ACID WITH ABOUT 1:10 RATIO OF PEPSIN (SIGMA, ST. LOUIS, MO). TISSUES WERE WEIGHTED, AND THEN INCUBATED OVERNIGHT AT 37°C WITH CONTINUOUS STIRRING. DIGESTED SAMPLES WERE CENTRIFUGED AND THE SUPERNATANT WAS USED FOR THE ANALYSIS WITH SIRCOL. THE PROTEIN CONCENTRATION WAS DETERMINED USING BRADFORD PROTEIN ASSAY KIT (BIORAD, RICHMOND, CA). CONTENT OF EACH SAMPLE WAS NORMALIZED TO TOTAL PROTEIN.

Histological analysis. BOTH THE TISSUE SAMPLES OF LUNG AND SKIN WERE FIXED IN 4% PARA-FORMALDEHYDE AND EMBEDDED IN PARAFFIN. SECTIONS OF 5 μm WERE STAINED EITHER WITH HEMATOXYLIN AND EOSIN (H&E) OR MASSON'S TRICHROME.

Statistical Analysis. RESULTS WERE EXPRESSED AS MEAN ± SD. THE DIFFERENCE BETWEEN TWO DIFFERENT CONDITIONS OR TREATMENTS WAS ASSESSED BY STUDENTS'T-TEST. A P-VALUE LESS THAN 0.05 WAS CONSIDERED STATISTICALLY SIGNIFICANT.

RESULTS

Gene and protein expression of *Col1a2*, *Ctgf* and *Sparc* in the fibroblasts from TBR1CA; Cre-ER mice with and without transfection of siRNAs

AS MEASURED BY QUANTITATIVE REAL-TIME PCR, *Col1a2*, *Ctgf*, AND *Sparc* SHOWED INCREASED EXPRESSION IN THE FIBROBLASTS FROM TBR1CA; Cre-ER MICE INJECTED WITH 4-OHT, IN WHICH TGFBR1 WAS CONSTITUTIVELY ACTIVE, COMPARED WITH THOSE IN TBR1CA; Cre-ER MICE INJECTED WITH OIL (FIGURE 1). THE FOLD-CHANGES OF EACH GENE IN 4-OHT-TREATED TBR1CA; Cre-ER FIBROBLASTS WERE 3.06 ± 1.41 FOR *Col1a2* ($P = 0.050$), 4.15 ± 1.18 FOR *Ctgf* ($P = 0.049$), AND 2.49 ± 0.63 FOR *Sparc* ($P = 0.017$), RESPECTIVELY. TO STUDY WHETHER INHIBITION OF SPARC INDUCED REDUCTION OF COLLAGEN IN THE FIBROBLASTS FROM CONSTITUTIVELY ACTIVE TGFBR1 MICE, WE TRANSFECTED

INTO CULTURED FIBROBLASTS OBTAINED FROM MICE INJECTED WITH 4-OHT. CTGF IS A DOWN-STREAM GENE IN THE PATHWAY (17-20). INHIBITION OF CTGF REDUCED EXPRESSION OF CTGF AND FIBROTIC EFFECT OF (19). WE USED CTGF SIRNA AS A POSITIVE CONTROL FOR INHIBITION OF COLLAGEN EXPRESSION. TRANSFECTION EFFICIENCY OF SIRNAS INTO FIBROBLASTS WAS DETECTED BY FLUORESCENT RNA DUPLEX GREEN TRANSFECTION INDICATOR (DHARMACON) AND WAS DETECTED TO BE OVER 80%. THE GENE EXPRESSION LEVELS FROM THE NON-TARGETING SIRNA TREATED FIBROBLASTS COMPARED WITH THOSE FROM SALINE-TREATMENT FIBROBLASTS, AND NO SIGNIFICANT DIFFERENCE WAS OBSERVED (1.05 $\pm$ 0.18-FOLDS FOR *Col1a2*, 1.14 $\pm$ 0.16-FOLDS FOR *Col3a1*, AND 1.12 $\pm$ 0.12-FOLDS FOR *Spoc1*).

THEREFORE, IN THE FOLLOWING STUDY, FIBROBLASTS WITH NON-TARGETING SIRNA TREATMENT WERE USED AS NEGATIVE CONTROLS. SEVENTY-TWO HOURS AFTER SPARC SIRNA OR CTGF SIRNA TREATMENT, SIGNIFICANT REDUCTIONS (95%) BY SPARC SIRNA AND *Ctgf* (64%) BY CTGF SIRNA WERE OBSERVED IN THE FIBROBLASTS (FIGURE 2A). IN PARALLEL, *Col1a2* SHOWED DECREASED EXPRESSION IN CTGF SIRNA TRANSFECTED FIBROBLASTS (27% AND 29% DECREASE WITH $P < 0.05$ FOR CTGF SIRNA AND SPARC SIRNA, RESPECTIVELY) (FIGURE 1). WESTERN BLOT ANALYSIS SHOWED A SIMILAR LEVEL OF TYPE I COLLAGEN BY EITHER SPARC SIRNA OR CTGF SIRNA TREATMENT. AS ILLUSTRATED IN FIGURE 2C, BOTH SPARC SIRNA AND CTGF SIRNA SHOWED SIGNIFICANT ATTENUATION OF COLLAGEN EXPRESSION IN FIBROBLASTS ($P = 0.009$ OR 0.015 , RESPECTIVELY). CTGF AND SPARC PROTEIN LEVELS ALSO SHOWED SIGNIFICANT REDUCTIONS BY SPARC SIRNA ($P = 0.056$ OR 0.0004 , RESPECTIVELY) OR CTGF SIRNA TREATMENT ($P = 0.002$ OR 0.0004 , RESPECTIVELY).

siRNAs ameliorated fibrosis in skin and reduced inflammation in lungs induced by bleomycin

THE STAINS OF MOUSE SKIN TISSUES (FIGURE 3) SHOWED THAT 4-WEEK INJECTIONS OF BLEOMYCIN INDUCED SIGNIFICANT FIBROSIS IN SKIN WHERE THE FAT CELLS WERE REPLACED BY FIBER BUNDLES. IN CONTRAST, COMPARED WITH NORMAL SKIN INJECTED WITH SALINE ONLY (FIGURE 3.). BLEOMYCIN-INDUCED SKIN TISSUES WITH CTGF SIRNA OR SPARC SIRNA SHOWED THAT MOST OF THE FAT CELLS STILL EXISTED WITHOUT PROMINENT FIBER BUNDLES (FIGURE 3.). MASSON'S TRICHROME STAINING OF SKIN TISSUES SHOWED THE SAME RESULTS. NOTABLY, INCREASED HAIR FOLLICLES WERE INCONSISTENTLY OBSERVED IN CTGF SIRNA AND SPARC SIRNA-TREATED BLEOMYCIN-INDUCED SKINS.

THE STAIN OF MOUSE LUNG TISSUES (FIGURE 4) SHOWED A SIGNIFICANT DISRUPTION OF THE ALVEOLI AND INFILTRATION OF INFLAMMATORY CELLS IN THE LUNGS INDUCED BY BLEOMYCIN (FIGURE 4). TREATMENT WITH CTGF SIRNA OR SPARC SIRNA, THE DISRUPTION OF THE ALVEOLI WAS IMPROVED.

INFILTRATING INFLAMMATORY CELLS (FIGURE 4.).

siRNAs attenuated over-expression of collagen and other fibrotic ECM genes induced by bleomycin in skin and lung tissues

BLEOMYCIN INJECTION INDUCED AN UP-REGULATION OF *Col1a1*, *Col3a1* AND *Sparc* IN BOTH SKIN (FIGURE 5A, $P = 0.028$, 0.016 , 0.049 AND 0.0005 , RESPECTIVELY) AND LUNG TISSUES (FIGURE 5B, 0.015 , 0.005 , 0.041 AND 0.056 , RESPECTIVELY) OF THE MICE. HOWEVER, IN CTGF SIRNA OR SPARC SIRNA TREATED MICE SKIN THAT ALSO RECEIVED BLEOMYCIN INJECTION, THE EXPRESSION OF THESE GENES APPEARED TO BE NORMAL IN SKIN TISSUES (FIGURE 5A, $P = 0.025$ AND 0.003 FOR EACH GENE IN CTGF TREATMENT, AND $P = 0.031$ AND 0.010 IN SPARC SIRNA TREATMENT), AND WERE SIGNIFICANTLY REDUCED IN LUNG TISSUES (ABOUT 2.7-FOLD REDUCTION FOR *Col1a1* AND 3.4-FOLD REDUCTION FOR *Col3a1* COMPARED TO BLEOMYCIN-INJECTED MICE WITHOUT SIRNA TREATMENT, $P < 0.05$ FOR BOTH) (FIGURE 5 B). SIMILARLY, COLLAGEN GENE EXPRESSION AND *Sparc* EXPRESSION WERE SIGNIFICANTLY REDUCED BY CTGF SIRNA AND CTGF SIRNA TREATMENT, RESPECTIVELY (FIGURE 5B). IN DETAIL, COLLAGEN GENE EXPRESSION IN BLEOMYCIN-INDUCED SKIN AND LUNGS, SPARC SIRNA TREATMENT REDUCED COLLAGEN GENE EXPRESSION IN BOTH SKIN AND LUNGS (2.6-FOLD REDUCTION IN BOTH WITH $P = 0.1$ AND 0.039 , RESPECTIVELY). SIMILARLY, CTGF SIRNA TREATMENT REDUCED *Sparc* EXPRESSION IN SKIN AND LUNGS (2.9-FOLD AND 1.5-FOLD REDUCTION WITH $P = 0.001$ AND 0.188 , RESPECTIVELY).

siRNAs reduced the collagen contents in bleomycin-induced mouse skin and lung samples: TO FURTHER EVALUATE ANTI-FIBROTIC EFFECTS OF SIRNAS ON THE FIBROGENESIS OF SKIN AND LUNG, COLLAGEN CONTENT, A KEY MARKER IN ASSESSING COLLAGEN DEPOSITION, WAS MEASURED IN THE PULMONARY SAMPLES. QUANTIFICATION OF TOTAL COLLAGEN IN SKIN SAMPLES WITH THE COLLAGEN ELISA SHOWED A 2.2-FOLD INCREASE IN BLEOMYCIN-INDUCED SKIN COMPARED WITH SALINE-INJECTED SKIN. CTGF SIRNA TREATMENT REDUCED THE COLLAGEN CONTENT TO 47.6% ($P = 0.03$) OF THAT IN BLEOMYCIN-INDUCED SKIN, AND SPARC SIRNA TREATMENT REDUCED THE COLLAGEN CONTENT TO 64.6% ($P = 0.001$) (FIGURE 6A). THERE WAS NO SIGNIFICANT DIFFERENCE OF COLLAGEN REDUCTION ($P = 0.08$) BETWEEN CTGF SIRNA TREATMENT AND SPARC SIRNA TREATMENT.

THE SIRNA TREATMENTS ALSO SHOWED A REDUCTION OF COLLAGEN IN THE LUNG TISSUES OF BLEOMYCIN-INDUCED MICE (FIGURE 6B). IN BLEOMYCIN-INDUCED MICE, COLLAGEN CONTENT WAS 2.2-FOLD HIGHER THAN THAT IN SALINE-INJECTED MICE. CTGF SIRNA TREATMENT REDUCED COLLAGEN CONTENT TO 47.6% ($P = 0.03$) OF THAT IN BLEOMYCIN-INDUCED MICE, AND SPARC SIRNA TREATMENT REDUCED COLLAGEN CONTENT TO 64.6% ($P = 0.001$) (FIGURE 6B).

WAS 3.6-FOLD HIGHER THAN THAT IN CONTROL MICE (SALINE-INJECTED MICE, $P = 0.0135$). IN SPARC SIRNA TREATED MICE THAT ALSO WERE BLEOMYCIN-INDUCED, COLLAGEN CONTENT WAS 68% ($P = 0.128$) OR 58% ($P = 0.019$) OF THAT IN BLEOMYCIN-INDUCED MICE WITHOUT SIRNA TREATMENT. NO SIGNIFICANT DIFFERENCE OF COLLAGEN CONTENT WAS FOUND BETWEEN SPARC SIRNA TREATED MICE AND BLEOMYCIN-INDUCED MICE WITHOUT SIRNA TREATMENT IN BLEOMYCIN-INJURED LUNGS ($P = 0.28$).

DISCUSSION

ALTHOUGH FIBROSIS IS USUALLY AN IRREVERSIBLE PATHOLOGICAL CONDITION, TARGETING OF THE EFFECTORS MAY REVERSE AN ACTIVE STATUS OF THE FIBROTIC PROCESS, AND SUBSEQUENTLY TGF- β SIGNALING PATHWAY IS ASSOCIATED WITH ACTIVE FIBROSIS (17). IT BEGINS WITH THE BINDING OF TGF- β LIGAND TO THE TYPE II RECEPTOR, WHICH CATALYSES THE PHOSPHORYLATION OF THE TYPE I RECEPTOR ON THE CELL MEMBRANE. THE TYPE I RECEPTOR THEN INDUCES THE PHOSPHORYLATION OF RECEPTOR-REGULATED SMADS (R-SMADS) THAT BIND THE COSMAD. THE PHOSPHORYLATED R-SMAD/COSMAD COMPLEX ENTERS THE NUCLEUS ACTING AS TRANSCRIPTION FACTORS TO REGULATE GENE EXPRESSION (18). CTGF (CONNECTIVE TISSUE GROWTH FACTOR) IS A DOWN-STREAM TARGET ACTIVATED BY THE TGF- β SIGNALING PATHWAY (19). ACTIVATION OF CTGF IS ASSOCIATED WITH PERSISTENT FIBROTIC CHANGES IN THE TISSUES, WHICH IS TYPICALLY REPRESENTED AS ACCUMULATION OF COMPONENTS INCLUDING COLLAGENS (20).

THE STUDIES DESCRIBED HERE UTILIZED THE FIBROBLASTS OBTAINED FROM THE TBR1^{CA} MICE. THESE FIBROBLASTS WERE INDUCED FOR CONSTITUTIVELY ACTIVE TGF- β AFTER TRANSFECTION OF SPARC SIRNA. THE FIBROBLASTS SHOWED A DECREASED EXPRESSION OF COL1A2 THAT WAS ORIGINALLY OVER-EXPRESSED IN TBR1^{CA}; CRE-ER MICE (FIGURE 2). THIS PHENOMENON SUGGESTS THAT SPARC INHIBITION MAY SUPPRESS FIBROTIC TGF- β SIGNALING. ALTHOUGH THE SPECIFIC MECHANISM FOR THIS SUPPRESSION IS UNKNOWN, PREVIOUS STUDIES HAVE DEMONSTRATED A MUTUAL REGULATORY RELATIONSHIP BETWEEN SPARC AND TGF- β SIGNALING (14,21-23). THIS NOTION ALSO IS SUPPORTED BY THE OBSERVATION OF AN OVER-EXPRESSION OF SPARC IN THE FIBROBLASTS OF TBR1^{CA} MICE (FIGURE 1). IT SHOULD BE NOTED THAT THE EXPRESSION OF TGF- β IN THE FIBROBLASTS WAS NOT REDUCED UPON SPARC INHIBITION. THESE RESULTS CONTRADICT OUR PREVIOUS REPORT OF PARALLEL INHIBITION OF SPARC AND CTGF EXPRESSION IN FIBROBLASTS BY SPARC SIRNA (14). A POSSIBLE EXPLANATION IS THAT OVER-EXPRESSION

CONSTITUTIVELY ACTIVATED SIGNALLING IN THESE FIBROBLASTS MAY CONFER RESISTANCE TO THE DOWN-REGULATORY EFFECT FROM SPARC SIRNA. HOWEVER, SUCH RESISTANCE APPEARED TO HAVE NO INFLUENCE ON ANY DOWN-REGULATORY EFFECT OF SPARC SIRNA ON COLLAGEN TYPE 1, CTGF IS NOT A SOLE CONTRIBUTOR TO COLLAGEN-ASSOCIATED FIBROSIS.

BLEOMYCIN INDUCED FIBROSIS IN MICE USUALLY OCCURS AFTER INFLAMMATION IN THE LUNGS IS UP-REGULATED (24). IN OUR APPLICATION OF SPARC SIRNA DEMONSTRATED THAT INHIBITION OF CTGF SIGNALLING SIGNIFICANTLY REDUCED INFLAMMATION AND FIBROSIS IN SKIN AND LUNGS INDUCED BY BLEOMYCIN. IN THE TREATMENT OF SKIN FIBROSIS, SPARC SIRNAS REDUCED FIBER BUNDLES ACCUMULATED IN THE SKIN AND MONONUCLEAR CELL INFILTRATES (FIGURE 3). IN ADDITION TO HISTOLOGICAL CHANGES, BLEOMYCIN-INDUCED SKIN TREATED WITH SPARC SIRNA SHOWED OVER 50% REDUCTION IN FIBER BUNDLES WITHOUT SPARC SIRNA TREATMENT (DATA NOT SHOWN). THE CHANGES OF TISSUE FIBROTIC MARKERS WERE CONFIRMED WITH SIGNIFICANTLY DECREASED COLLAGEN GENE EXPRESSION (FIGURE 5A). FIBRILLAR COLLAGEN IN THE SKIN TISSUES ALSO SHOWED AN AVERAGE OF 35.4% REDUCTION IN FIBER BUNDLES TREATMENT (FIGURE 6A).

IN THE TREATMENT OF LUNGS, SPARC SIRNA REDUCED THE DISRUPTION OF THE ALVEOLI IN THE LUNGS (FIGURE 4), WHICH WAS ACCOMPANIED WITH ATTENUATED GENE EXPRESSION AND PROTEIN LEVELS OF COLLAGENS AS COMPARED TO THAT WITHOUT SIRNA TREATMENT (FIGURE 5B AND 6B). HOWEVER, THE HISTOLOGICAL EXAMINATIONS AND THE CHANGED LEVELS OF COLLAGEN GENES AND PROTEINS IN THE LUNGS APPEARED TO BE LESS PERFECT AS COMPARED TO THAT IN NORMAL CONTROL MICE. ON THE OTHER HAND, HIGHER LEVELS OF GENE EXPRESSION OF *CTGF* AND *Col3A1*, AND PROTEIN CONTENT OF COLLAGEN WERE OBSERVED IN BLEOMYCIN-INDUCED LUNG TISSUES WHEN THEY WERE COMPARED TO THE NORMAL CONTROL MICE (5.2-FOLD, 6.7-FOLD AND 3.6-FOLD INCREASE VS. 3.8-FOLD, 2.8-FOLD AND 2.2-FOLD INCREASE IN SKIN). WHICH SUGGESTED THAT TISSUE DAMAGE AND FIBROSIS IN LUNG MIGHT BE MORE SEVERE THAN IN SKIN. IN THIS CASE, TREATMENT OF BLEOMYCIN-INDUCED LUNG DAMAGE MIGHT PRESENT A BIGGER CHALLENGE THAN IN SKIN, AND THE SIRNA TREATMENT THROUGH INTRATRACHEAL INSTILLATION MAY NEED FURTHER OPTIMIZATION. THESE NOTIONS WERE SUPPORTED BY SIMILAR FINDINGS IN THE TREATMENT OF SKIN WITH SPARC SIRNA, A POSITIVE CONTROL FOR ANTI-FIBROTIC EFFECTS.

NEVERTHELESS, SPARC INHIBITION SHOWED A CLEAR ANTI-FIBROTIC EFFECT IN BLEOMYCIN-INDUCED LUNG TISSUES. NOTABLY, THESE CHANGES WERE ACCOMPANIED WITH A SIGNIFICANT DOWNREGULATION OF SPARC THAT PARALLELED SPARC UP-REGULATION IN BLEOMYCIN-INDUCED TISSUES. THESE OBSERVATIONS, COMBINING WITH THE RESULTS OF ANTI-FIBROTIC EFFECTS OF SPARC SIRNA IN FIBROBLAST-LIKE KNOCK-IN MOUSE FURTHER SUPPORT A MUTUALLY REGULATORY RELATIONSHIP BETWEEN SPARC AND TGF β SIGNALING.

IN SUMMARY, STUDIES DESCRIBED HERE CONSISTENTLY DEMONSTRATED THAT INHIBITION OF SPARC SIGNIFICANTLY REDUCED COLLAGEN EXPRESSION IN GENETIC TGF β R1 FIBROBLAST MODEL AND *in vivo* BLEOMYCIN-INDUCED FIBROTIC MOUSE MODEL. THIS IS A FIRST ATTEMPT TO EXAMINE THE EFFECTS OF SPARC INHIBITION IN SKIN AND LUNG. THE RESULTS OBTAINED FROM THESE STUDIES PROVIDE FAVORABLE EVIDENCE THAT SPARC MAY BE USED AS A BIO-TARGET FOR APPLICABLE THERAPIES.

Funding

THIS STUDY WAS SUPPORTED BY THE GRANT FROM THE ARMY, MEDICAL RESEARCH AND ACQUISITION ACTIVITY, GRANT NUMBER PR064803 TO ZHOU AND THE NATIONAL INSTITUTE OF HEALTH, GRANT NUMBER P50 AR054144 TO ARNETT

Figure legend

Figure 1. COMPARISON OF GENE EXPRESSION BETWEEN THE FIBROBLASTS FROM ^{6A}CTGFR MICE INJECTED WITH OIL AND 4-OHT. THE EXPRESSION LEVEL OF EACH GENE IN THE FIBROBLASTS FROM ^{6A}CTGFR MICE INJECTED WITH OIL WAS NORMALIZED TO 1. BARS SHOW THE MEAN $\pm$ SD RESULT OF 3 INDEPENDENT EXPERIMENTS PERFORMED IN TRIPLICATE. *, $p < 0.05$.

Figure 2. GENE AND PROTEIN EXPRESSION IN ORIGINAL AND SIRNA TREATED FIBROBLASTS FROM ^{6A}CTGFR MICE INJECTED WITH 4-OHT. (A) RELATIVE TRANSCRIPT LEVELS OF COL1A2, CTGF, AND SPARC IN THE FIBROBLAST LINES WITH NON-TARGETING SIRNA TREATMENT WAS NORMALIZED TO 1. *, $P < 0.05$. (B) WESTERN BLOT ANALYSIS OF TYPE I COLLAGEN AND SPARC IN THE FIBROBLASTS FROM CONSTITUTIVELY ACTIVE TGFR1 MICE, WITH CTGF SIRNA TRANSFECTION. N = NON-TARGETING SIRNA TREATMENT; C = CTGF SIRNA TREATMENT; S = SPARC SIRNA TREATMENT. (C) DENSITOMETRIC ANALYSIS OF WESTERN BLOTS FOR PROTEIN LEVELS OF COL1, CTGF, AND SPARC. COMPARED TO NON-TARGETING SIRNA TREATMENT, CTGF SIRNA OR SPARC SIRNA TREATMENT SHOWED SIGNIFICANT REDUCTION OF COL1 ($P = 0.015$ OR 0.009 RESPECTIVELY), CTGF ($P = 0.003$ OR 0.001 RESPECTIVELY) AND SPARC ($P = 0.355$ OR 0.0004 , RESPECTIVELY).

Figure 3. REPRESENTATIVE HISTOLOGICAL ANALYSIS OF HE AND TRICHROME STAIN OF MICE WITH DIFFERENT TREATMENTS FOR 4 WEEKS IN LOW (4 X) AND HIGH MAGNIFICATIONS (20 X). A. INJECTION WITH SALINE (NEGATIVE CONTROL) ONLY; B. INJECTION WITH BLEOMYCIN ONLY; C. INJECTION WITH BLEOMYCIN AND TREATMENT WITH SPARC SIRNA; D. INJECTION WITH BLEOMYCIN AND TREATMENT WITH CTGF SIRNA.

Figure 4. REPRESENTATIVE HISTOLOGICAL FEATURES OF HE AND TRICHROME STAIN OF MICE WITH DIFFERENT TREATMENTS INTRATRACHEALLY IN LOW (4 X) AND HIGH MAGNIFICATIONS (20 X). A. INJECTION WITH SALINE (NEGATIVE CONTROL) ONLY; B. INJECTION WITH BLEOMYCIN ONLY ON DAY 0; C. INJECTION WITH BLEOMYCIN ON DAY 0 AND SPARC SIRNA ON DAYS 2, 5, AND 12; D. INJECTION WITH BLEOMYCIN ON DAY 0 AND CTGF SIRNA ON DAYS 2, 5, AND 12.

Figure 5. GENE EXPRESSION IN SKIN OR LUNG SAMPLES WITH DIFFERENT TREATMENTS. (A) RELATIVE TRANSCRIPT LEVELS OF *Col1a1*, *Col3a1*, *Ctgf*, AND *Sparg* IN SIRNA-TREATED OR UNTREATED BLEOMYCIN-INDUCED SKINS OR LUNGS, RESPECTIVELY. THE EXPRESSION LEVEL OF EACH GENE IN LUNG SAMPLE FROM SALINE TREATED MICE WAS NORMALIZED TO 1. *, $P < 0.05$.

Figure 6. COLLAGEN CONTENTS IN SKIN (A) OR LUNG (B) SAMPLES WITH DIFFERENT TREATMENTS. COLLAGEN CONTENT IN THE SKIN OR LUNG SAMPLE FROM SALINE TREATED MICE WAS NORMALIZED TO 1. A: SALINE; B: BLEOMYCIN; B + C: BLEOMYCIN AND CTGF SIRTAS; B + S: BLEOMYCIN AND SPARC SIRNA. *, $P < 0.05$.

Figure 1.




Figure 2.




Figure 3.




Figure 4.




Figure 5.





Figure 6.



Peer Review

REFERENCES

1. ABDELAZIZ MM, SAMMAN YS, WALI SO, HAMAD MM. (2005) TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS: IS THERE ANYTHING NEW?. *Respiratory* 106(3):289-289.
2. TOME S, LUCEY MR. (2004) REVIEW ARTICLE: CURRENT MANAGEMENT OF ALCOHOLIC LIVER DISEASE. *Aliment Pharmacol Ther.*, 19(7):707-714.
3. HENNESS S, WIGLEY FM. (2007) CURRENT DRUG THERAPY FOR SCLERODERMA AND SECONDARY SCLERODERMA: A PHARMACOLOGICAL REVIEW. *Curr Opin Rheumatol* 19(6):611-618.
4. KUHN C, MASON RJ. IMMUNOLOCALIZATION OF SPARC, TENASCIN, AND THROMBOSPONDIN IN PULMONARY FIBROSIS. (1995) *Am J Pathol* 141:1759-1769.
5. PICHLER RH, HUGO C, SHANKLAND SJ, REED MJ, BASSUK JA, ANDOH TF, SCHWARTZ SM, WILSON WM, ALPERS CE, SAGE EH, et al. (1996) SPARC IS EXPRESSED IN RENAL INTERSTITIAL FIBROSIS AND RENAL VASCULAR INJURY. *J Am Soc Nephrol* 7:1989.
6. FRIZELL E, LIU SL, ABRAHAM A, OZAKI I, EGHBAI M, SAGE EH, ZERN MA. (1995) EXPRESSION OF SPARC IN NORMAL AND FIBROTIC LIVERS. *Hepatology* 21:1547-1554.
7. RAINES EW, LANE TF, IRUELA-ARISPE ML, ROSS R, SAGE EH. (1992) THE EXTRACELLULAR MATRIX GLYCOPROTEIN SPARC INTERACTS WITH PLATELET-DERIVED GROWTH FACTOR (PDGF) AND INHIBITS THE BINDING OF PDGF TO ITS RECEPTORS. *Proc Natl Acad Sci USA* 89:12841-12854.
8. ZHOU X, TAN FK, REVEILLE JD, WALLIS D, MILEWICZ DM, AHN C, WANG A, ARNETT FC. (2000) ASSOCIATION OF NOVEL POLYMORPHISMS WITH THE EXPRESSION OF SPARC IN NORMAL SKIN AND WITH SUSCEPTIBILITY TO SCLERODERMA. *Arthritis Rheum* 43:2090-2099.
9. VUORIO T, KÄHÄRI VM, BLACK C, VUORIO E. (1991) EXPRESSION OF OSTEOCALCIN, DEFA-1, AND TRANSFORMING GROWTH FACTOR-BETA 1 GENES IN FIBROBLASTS CULTURED FROM PATIENTS WITH SCLEROSIS AND MORPHEA. *J Rheumatol* 18:247-251.
10. MACKO RF, GELBER AC, YOUNG BA, LOWITT MH, WHITE B, WIGLEY FM, GOLDBLUM SE. (1999) INCREASED CIRCULATING CONCENTRATIONS OF THE COUNTERADHESIVE PROTEIN THROMBOSPONDIN-1 IN SYSTEMIC SCLEROSIS (SCLERODERMA). RELATIONSHIP TO PLATELET CELL ACTIVATION. *J Rheumatol* 26:2565-2570.
11. DAVIES CA, JEZIORSKA M, FREEMONT AJ, HERRICK AL. (2006) EXPRESSION OF OSTEOCALCIN AND MATRIX GLA PROTEIN IN SCLERODERMA PATIENTS WITH ANTI-TOPOTROPIC ANTIBODIES. *Rheumatology (Oxford)* 45(11):1349-1355.
12. BREKKEN RA, SAGE EH. (2001) SPARC, A MATRICELLULAR PROTEIN: AT THE CROSSROADS OF CELLULAR AND MATRIX BIOLOGY. *Matrix Biol.*, 19:816-827.
13. SCHIEMANN BJ, NEIL JR, SCHIEMANN WP. (2003) SPARC INHIBITS EPITHELIAL CELL PROLIFERATION PART THROUGH STIMULATION OF THE TRANSFORMING GROWTH FACTOR-BETA1 SIGNALING PATHWAY. *Cell Growth* 14(10):3977-3988.
14. ZHOU X, TAN FK, GUO X, WALLIS D, MILEWICZ DM, XUE S, ARNETT FC. (2005) SMALL INTERFERING RNA INHIBITION OF SPARC ATTENUATES THE PROFIBROTIC EFFECT OF TRANSFORMING GROWTH FACTOR-BETA1 ON CULTURED NORMAL HUMAN FIBROBLASTS. *Arthritis Rheum.*, 52:257-261.
15. STRANDJORD TP, MADTES DK, WEISS DJ, SAGE EH. (1999) COLLAGEN ACCUMULATION IS INCREASED IN SPARC-NUL MICE WITH BLEOMYCIN-INDUCED PULMONARY FIBROSIS. *Am J Physiol* 276:R1562-R1568.

16. SONNYLAL S, DENTON CP, ZHENG B, KEENE DR, HE R, ADAMS HP, VANPELT CS, GENG YJ, JM, BEHRINGER RR, DE CROMBRUGGHE B. (2007) POSTNATAL INDUCTION OF TRANSFORMING GROWTH FACTOR SIGNALING IN FIBROBLASTS OF MICE RECAPITULATES CLINICAL, HISTOLOGIC FEATURES OF SCLERODERMA. *Arthritis Rheum*, 56:3441-3444.
17. BORDER WA, NOBLE NA. (1994) TRANSFORMING GROWTH FACTOR BETA1 IN TISSUE FIBROSIS. *Med.*, 331(19):1286-1292.
18. BLOBE GC, SCHIEMANN WP, LODISH HF. (2000) ROLE OF TRANSFORMING GROWTH FACTOR BETA1 IN HUMAN DISEASE. *N ENGL J MED.*, 342(18):1350-1358.
19. GROTE DORST GR. (1997) CONNECTIVE TISSUE GROWTH FACTOR: A MODULATOR OF TISSUE FIBROBLASTS. *Cytokine Growth Factor Rev*, 8:161-179.
20. CHUJO S, SHIRASAKI F, KAWARA S, INAGAKI Y, KINBARA T, KIGUCHI NAOMI, Takehara K. (2005) CONNECTIVE TISSUE GROWTH FACTOR CAUSES PERSISTENT PROALPHA2(I) COLLAGEN INDUCED BY TRANSFORMING GROWTH FACTOR BETA1 FIBROSIS . *Model Physiol*, 203:447-456.
21. SCHIEMANN BJ, NEIL JR, SCHIEMANN WP. (2003) SPARC INHIBITS EPITHELIAL CELL PROLIFERATION PART THROUGH STIMULATION OF THE TRANSFORMING GROWTH FACTOR BETA1-Cell, 14:3977-3988.
22. ZHOU XD, XIONG MM, TAN FK, GUO XJ, ARNETT FC. (2006) SPARC. AN UPSTREAM REGULATOR OF CONNECTIVE TISSUE GROWTH FACTOR IN RESPONSE TO TRANSFORMING GROWTH FACTOR BETA1. *Arthritis Rheum*, 54:3885-3889.
23. FRANCKI A, MCCLURE TD, BREKKEN RA, MOTAMED K, MURRI C, WANG T, SAGE EH. (2004) SPARC REGULATES TGF-BETA1-DEPENDENT SIGNALING IN PRIMARY GLOMERULAR MESANGIAL CELLS. *Biochem*, 91:915-925.
24. CUTRONEO KR, WHITE SL, PHAN SH, EHRLICH HP. (2007) THERAPIES FOR BLEOMYCIN INDUCED TISSUE FIBROSIS THROUGH REGULATION OF TGF-BETA1 INDUCED COLLAGEN BETA1 EXPRESSION. *Cell Physiol*, 211:585-589.